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BACKGROUND: Myocardial metabolic impairment is a major feature in 
chronic heart failure. As the major coenzyme in fuel oxidation and oxidative 
phosphorylation and a substrate for enzymes signaling energy stress and 
oxidative stress response, nicotinamide adenine dinucleotide (NAD+) is emerging 
as a metabolic target in a number of diseases including heart failure. Little is 
known on the mechanisms regulating homeostasis of NAD+ in the failing heart.
METHODS: To explore possible alterations of NAD+ homeostasis in the failing 
heart, we quantified the expression of NAD+ biosynthetic enzymes in the human 
failing heart and in the heart of a mouse model of dilated cardiomyopathy (DCM) 
triggered by Serum Response Factor transcription factor depletion in the heart 
(SRFHKO) or of cardiac hypertrophy triggered by transverse aorta constriction. We 
studied the impact of NAD+ precursor supplementation on cardiac function in 
both mouse models.
RESULTS: We observed a 30% loss in levels of NAD+ in the murine failing heart 
of both DCM and transverse aorta constriction mice that was accompanied by 
a decrease in expression of the nicotinamide phosphoribosyltransferase enzyme 
that recycles the nicotinamide precursor, whereas the nicotinamide riboside 
kinase 2 (NMRK2) that phosphorylates the nicotinamide riboside precursor 
is increased, to a higher level in the DCM (40-fold) than in transverse aorta 
constriction (4-fold). This shift was also observed in human failing heart biopsies 
in comparison with nonfailing controls. We show that the Nmrk2 gene is an 
AMP-activated protein kinase and peroxisome proliferator-activated receptor 
α responsive gene that is activated by energy stress and NAD+ depletion 
in isolated rat cardiomyocytes. Nicotinamide riboside efficiently rescues 
NAD+ synthesis in response to FK866-mediated inhibition of nicotinamide 
phosphoribosyltransferase and stimulates glycolysis in cardiomyocytes. 
Accordingly, we show that nicotinamide riboside supplementation in food 
attenuates the development of heart failure in mice, more robustly in DCM, 
and partially after transverse aorta constriction, by stabilizing myocardial NAD+ 
levels in the failing heart. Nicotinamide riboside treatment also robustly increases 
the myocardial levels of 3 metabolites, nicotinic acid adenine dinucleotide, 
methylnicotinamide, and N1-methyl-4-pyridone-5-carboxamide, that can be used 
as validation biomarkers for the treatment.
CONCLUSIONS: The data show that nicotinamide riboside, the most energy-
efficient among NAD precursors, could be useful for treatment of heart failure, 
notably in the context of DCM, a disease with few therapeutic options.
© 2017 American Heart Association, Inc.
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Despite progress in therapeutic advances, mortality remains high in congestive heart failure (HF), cre-ating a need for new evidence-based and cost-ef-
fective treatments. Failure of cardiomyocyte bioenerget-
ics is a key issue in HF that is not well addressed in current 
therapeutics.1,2 We focused our attention on pathways 
that regulate nicotinamide adenine dinucleotide (NAD+) 
homeostasis in the failing heart, which has emerged as 
a new avenue for the development of metabolic therapy 
of HF.3,4 NAD+ is the major hydride transfer coenzyme in 
fuel oxidation and mitochondrial ATP generation and is 
the precursor for NADPH, which is required for anabolic 
pathways and reactive oxygen species detoxification.5,6 
In addition, NAD+ is an essential substrate of enzymes 
including sirtuins and poly(ADP-ribose) polymerases, 
which are important in responding to altered nutritional 
status and genotoxic stress.6,7 Sirtuins perform NAD+-de-
pendent deacylation of protein Lys residues modified by 
acetyl coenzyme A (Ac-CoA) derived acyl groups.8 Sirtu-
ins regulate nuclear gene expression, and mitochondrial 
enzyme activities, as well, and can play a protective role 
in the heart,9 although chronic overactivation may be 
deleterious.10 Poly(ADP-ribose) polymerase 1 is activated 
by reactive oxygen species–induced DNA lesions, and 
could deplete myocardial NAD+ stores in HF.11 In situ-
ations of physiological equilibrium, biosynthetic path-
ways relying on dietary sources of tryptophan and NAD+ 
precursor vitamins counterbalance the consumption of 
NAD+ by signaling enzymes. However, dietary precursors 
may become insufficient to maintain the NAD+ metabo-
lome in pathological conditions, thereby necessitating 
supplementation of NAD+ precursor.5,12,13
The homeostasis of NAD+ and regulation of NAD+ 
biosynthetic enzymes have not been studied in dilated 
cardiomyopathy (DCM), a leading cause of heart trans-
plant.14 We previously generated a powerful model of 
nonischemic DCM in mice triggered by cardiac-specific 
inducible inactivation of Serum Response Factor (SRF-
HKO model).15–18 SRF is a major transcriptional regulator 
of genes and microRNAs involved in contractility, and 
in energy flux and calcium handling, as well.15,17,18 The 
SRF pathway is altered in the human failing heart19,20 
and in animal models of DCM.21,22 The heart of SRFHKO 
mutant mice display an early downregulation of myofi-
brillar creatine kinase (CK) activity encoded by the Ckm 
gene, which is followed by repression of enzymes of 
fatty acid β-oxidation and loss of ATP, thus recapitu-
lating the transitional steps toward energy failure and 
cardiac structural remodeling in HF.18
Here, we show that NAD+ homeostasis is altered at 
an early stage in the heart of SRFHKO mice with a strik-
ing induction of the nicotinamide riboside kinase 2 
(NMRK2) pathway for NAD+ synthesis. Nmrk2 gene is 
1 of 2 mammalian paralogs of the yeast NRK1 gene 
that was discovered as a eukaryotic route to NAD+ from 
nicotinamide riboside (NR).23 Given the activity of NR in 
promoting sirtuin activity and restoring metabolic bal-
ance in a variety of model organisms,13,24–28 we aimed to 
test whether NR might treat HF in SRFHKO mice and in the 
pressure overload hypertrophy model induced by trans-
verse aorta constriction (TAC). Here, we show that NR 
greatly protects cardiac function by virtue of improved 
citrate and Ac-CoA metabolism and antioxidant gene 
expression. Because NR is orally available in people,29 
our data rationalize clinical testing of NR in human HF.
METHODS
The data, analytic methods, and study materials will be made 
available from the corresponding author on request to other 
researchers for purposes of reproducing the results or repli-
cating the procedure. Detailed methods are available in the 
online-only Data Supplement.
Clinical Perspective
What Is New?
• Myocardial nicotinamide adenine dinucleotide 
(NAD) coenzyme levels are depressed in mouse 
models of heart failure.
• An expression shift occurs in murine and human 
failing hearts in which the normally predominant 
nicotinamide phosphoribosyltransferase enzyme 
using nicotinamide as a precursor for NAD+ synthe-
sis is repressed, whereas the nicotinamide riboside 
kinase 2 enzyme using the nucleoside nicotinamide 
riboside (NR) is strongly upregulated.
• The nicotinamide riboside kinase 2pathway is acti-
vated by energy stress in an AMP-activated protein 
kinase α/peroxisome proliferator-activated receptor 
α–dependent manner in cardiomyocytes.
• NR-supplemented diet administrated to murine 
models of dilated cardiomyopathy or pressure over-
load-induced heart failure restores myocardial NAD 
levels and preserves cardiac function.
• NR increases glycolysis, and citrate and acetyl-coen-
zyme A metabolism, as well, in cardiomyocytes.
What Are the Clinical Implications?
• NR is the most energetically favorable NAD precur-
sor and was recently shown to be uniquely and 
orally bioavailable in humans in a phase I clinical 
trial.
• NR-supplemented diet could help patients who 
have heart failure to cope with limited myocardial 
ATP supply by restoring NAD coenzyme levels and 
associated signaling.
• NR-supplemented diet has been shown in sev-
eral studies to enhance metabolic flexibility in the 
context of obesity and diabetes mellitus and to 
improve muscle function, justifying that NR is put 
in the front line for metabolic therapy of heart fail-
ure syndrome in which these functions are altered.
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Patients
Left ventricular (LV) myocardium was obtained from terminally 
failing human hearts of 4 patients (mean age 54 years±7, SD) 
at the time of transplantation at the Hôpitaux Universitaires 
de Strasbourg as previously published with approval of the 
Hôpitaux Universitaires de Strasbourg ethics committee.30 All 
patients gave informed consent. Patients’ characteristics are 
detailed in Table I in the online-only Data Supplement. The 
investigations conformed to the principles of the Declaration 
of Helsinki. Control hearts were obtained from the depart-
ment of Pharmacology and Pharmacotherapy, University 
of Szeged, Szeged, Hungary. Experimental protocols were 
approved by the Ethical Review Board of the Medical Center 
of the University of Szeged and by the Scientific and Research 
Ethical Committee of the Medical Scientific Board at the 
Hungarian Ministry of Health (ETT-TUKEB; No. 51–57/1997 
OEj and 4991-0/2010-1018EKU).
Transgenic Mice 
All experiments with animals conformed to the Directive 
2010/63/EU of the European Parliament and were approved 
by the ethics committee Charles Darvin #5 (agreement 
00369.01). See online-only Data Supplement for details on 
SRF inactivation protocol.
NR Supplementation
SRFHKO and control (Sf/Sf) mice were administered A04 rodent 
maintenance diet (Scientific Animal Food Engineering) sup-
plemented with NR chloride provided by Chromadex. See 
online-only Data Supplement for details.
Transcriptomic Analysis
Transcriptomic data are available on NCBI Gene Expression 
Database, Accession number GSE84142.
Statistical Analysis
Animals were randomly assigned into different treatment 
groups. To assess significance, we performed Student t test 
for independent samples when the experimental design com-
pared only 2 groups, or 1-way ANOVA for multiple group 
comparisons, or 2-way factorial ANOVA for independent fac-
tors when appropriate. Tukey tests were used for comparison 
of specific experimental groups when 1-way ANOVA gave a 
P value of <0.05 or, in the case of 2-way ANOVA for interac-
tion, a P value of <0.05. Values are expressed as mean±SEM.
Supplemental Information
Supplemental information includes supplemental methods, 9 
supplemental figures, and 6 supplemental tables.
RESULTS
NMRK2 Pathway Is Activated in the 
Failing Heart of SRFHKO Mice
Transcriptome analyses in SRFHKO mice at baseline or af-
ter phenylephrine α-adrenergic stimulation16 revealed 
that the Nmrk2 gene was induced at an early stage in 
the SRFHKO heart and rose continuously during establish-
ment of HF (Figure 1A and Table II in the online-only Data 
Supplement). The transcript for the ectoenzyme NT5E 
(CD73) that hydrolyzes extracellular NAD+ and nicotin-
amide mononucleotide (NMN) to NR, the substrate of 
NMRK2 kinase31 also increased in SRFHKO hearts (Table 
II in the online-only Data Supplement). In contrast, the 
transcripts encoding nicotinamide phosphoribosyltrans-
ferase (NAMPT), the enzyme converting nicotinamide 
(NAM) to NMN, and purine nucleoside phosphorylase 
(PNP), which converts NR to NAM,32 were depressed 
on phenylephrine treatment in SRFHKO hearts (Table II 
in the online-only Data Supplement). Genes involved in 
the tryptophan and nicotinic acid pathways for NAD+ 
synthesis were not altered (Figure 1A and Table II in the 
online-only Data Supplement).
Modulation of Nmrk2 and Nampt gene expression 
detected by transcriptomics was corroborated at the 
mRNA and protein level (Figure  1B through 1D). We 
observed a similar shift in human patients from pre-
dominant expression of NAMPT in healthy hearts to in-
creased NMRK2 and depressed NAMPT in failing hearts 
(Figure 1D, Table II in the online-only Data Supplement). 
In mouse heart sections, NMRK2 protein localizes at the 
proximity of sarcolemma in controls (Figure 1E). The sig-
nal was strongly enhanced and spread to cytoplasm in 
SRFHKO cardiomyocytes.
At day 15 after SRF inactivation, there was a 30% 
loss of NAD (representing the sum of NAD+ and NADH) 
(Figure 1F, see Methods in the online-only Data Supple-
ment for details). The gene expression pattern (Nt5e 
and Nmrk2 up with Pnp and Nampt down) suggested 
that cardiac tissue is attempting to mobilize and utilize 
NR as an NAD+ precursor while not increasing NAM us-
age. We tested this hypothesis by intraperitoneal ad-
ministration of NR and NAM to SRFHKO mice from day 8 
to 15. Consistent with this hypothesis, myocardial NAD 
levels were preserved by NR but not by NAM (Figure 1F). 
Srf and Nmrk2 expression levels were not changed by 
these treatments (Figure  1G and 1H). Because NR is 
orally available,26,29 we tested an NR-supplemented diet 
for 2 weeks. Myocardial NAD levels were reduced in 
this second series of SRFHKO mice in comparison with 
controls and rescued by NR administration (Figure 1I).
NR Preserves Cardiac Function in the 
SRFHKO Heart
We hypothesized that NR supplementation of food 
might be beneficial for cardiac function in the context 
of DCM. We fed control and mutant SRFHKO mice a 
standard chow diet or NR-supplemented diet to reach a 
dose of 400 mg/kg of body weight per day from day 5 
to 50, a period in which untreated SRFHKO mice develop 
DCM and progress toward HF.15–18 NR diet induced a 
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Figure 1. Activation of the Nmrk2 gene in dilated cardiomyopathy. 
A, Biosynthetic NAD+ pathways in mammalian cells. NA (nicotinic acid), NAM, NR, and TRP enter cells through special-
ized transport systems. Extracellular NAD+ and NMN are hydrolyzed to NR by the ectonucleotidase CD73. In the de novo 
pathway, TRP is converted to kynurenin (KYN) by IDO and TDO enzymes, and then into quinolic acid (QA) in 4 steps 
(not detailed). QA, NA, and NAM are phosphoribosylated by QPRT, NAPRT1, and NAMPT enzymes, respectively, to form 
mononucleotides NAMN and NMN. NR is phosphorylated by NMRK enzymes to form NMN. NR can be converted to NAM 
by PNP. NAMN and NMN are adenylated by the NMNAT enzymes to form the dinucleotides NAAD+ and NAD+. NAAD+ is 
amidated by NADSYN1. Genes increased in SRFHKO heart are highlighted in green and those repressed in red (see accom-
panying Table II in the online-only Data Supplement). Inhibitors are shown in blue. B and C, RT qPCR analysis of Nmrk2 
and Nampt mRNA fold change (FC) in SRFHKO hearts at different days (D) after SRF inactivation. D, Western blot analysis 
of NMRK2 and NAMPT protein in control and failing human hearts and control and SRFHKO mouse hearts at D45. GAPDH 
is used as loading control. All human and mouse samples were analyzed on single blot, but 2 lanes separating that 
showed signs of protein degradation and aberrant migration pattern were cut out of the picture. Right, Ratio of NMRK2/
NAMPT in human samples. E, Control and SRFHKO mutant heart sections stained for NMRK2 (red) and vinculin (green) at 
D45. White bar in upper left panel=20 µm. F through H, NAM or NR (30 µmol) were injected intraperitoneally from D8 
to 15 (400 mg/kg per day) to control and SRFHKO mice. Vehicle: saline solution. F, Myocardial NAD+ levels. G and H, RT 
qPCR analysis of Srf and Nmrk2 mRNA levels. I, Myocardial NAD levels in control and SRFHKO mice fed regular chow diet 
(CD) or NR-enriched diet (0.22%. 400–450 mg/kg per day) from D5 to 20. Throughout the figure, data are expressed as 
mean±SEM. Statistical analysis: One-way ANOVA (B, C) or 2-way factorial ANOVA for independent samples (F through I). 
¶¶P≤0.01, ¶¶¶P≤0.001 for the genotype effect; §§P≤0.01 for the NR treatment effect; ii P≤0.01 for the interaction effect. 
Post hoc Tukey test: asterisks indicate statistical significant difference between any group versus the control CD (or vehicle) 
group: *P≤0.05. **P≤0.01. ***P≤0.001. # P≤0.05 for the effect of NR within the SRFHKO group. A t test was used for 
the graph at the right of D: ** P≤0.01. FC indicates fold change over control group; IDO, indoleamine 2,3-dioxygenase; 
NAAD, nicotinic acid adenine dinucleotide; NAD, nicotinamide adenine dinucleotide; NAM, nicotinamide; NAMN, nicotinic 
acid mononucleotide; NAMPT, nicotinamide phosphoribosyltransferase; NMN, nicotinamide mononucleotide; NMNAT, 
nicotinamide mononucleotide adenylyltransferease; NMRK, nicotinamide riboside kinase; NR, nicotinamide riboside; PNP, 
purine nucleoside phosphorylase; QPRT, quinolinate phosphoribosyltransferase; RT qPCR, quantitative reverse transcription 
polymerase chain reaction; SRF, Serum Response Factor; TDO, tryptophan 2,3-dioxygenase; and TRP, tryptophan. 
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Figure 2. NR supplementation in diet prevents the onset of heart failure and dilatation. 
A, CD- or NR-supplemented diet (0.22%) was given ad libitum to control and SRFHKO mice from day 5 after SRF inactivation 
to the end of the experiment. Body weight was monitored throughout the period. Data are expressed as mean % weight 
variation±SEM, in comparison with weight at day 5. A 2-factor ANOVA with repeated measures on 1 factor was used for sta-
tistical analysis. §§§P≤0.001 for the time effect; iii, P≤0.001 for the interaction effect. Post hoc Tukey test: *P<0.05, **P<0.01, 
***P<0.001 for any time point versus day 5 within a group; #P≤0.05 for the NR treatment in SRFHKO group. B through O, 
Cardiac parameters of control and SRFHKO mutant were analyzed in M-Mode echocardiography between  day 45 and day 47. 
B, Heart rate; C, left ventricle (LV) mass index; D, LV ejection fraction; E, fractional shortening; F and G, LV end-systolic diam-
eter (F) and volume (G); H and I, LV end-diastolic diameter (H) and volume (I); J and K, LV posterior wall thickness in systole 
(J) and diastole (K); L and M interventricular septum thickness in systole (L) and diastole (M); N, H/R: LV thickness (H) to radius 
(R) ratio; and O, stroke volume. Dimensions were normalized by the body weight. Data are expressed as mean±SEM. Statisti-
cal analysis: 2-way factorial ANOVA for independent samples. ¶¶P≤0.01, ¶¶¶P≤0.001 for the genotype effect; §P≤0.05, 
§§P≤0.01, §§§P≤0.001 for the NR treatment effect; i P≤0.05, ii P≤0.01, iii P≤0.001 for the interaction effect. Post hoc Tukey 
test: asterisks indicate statistically significant difference versus the control CD group: *P≤0.05, **P≤0.01, ***P≤0.001. 
#P≤0.05, ##P≤0.01 for the effect of NR within the SRFHKO group. CD indicates chow diet; CONT, control; EDV, end-diastolic 
volume; ESV, end-systolic volume; FS, fractional shortening; IVSThd, interventricular septum thickness in diastole; IVSThs, in-
terventricular septum thickness in systole; LVEF, left ventricular ejection fraction; LVEDd, left ventricular end-diastolic diameter; 
LVESd, left ventricular end-systolic diameter; LVMI, left ventricular mass index; NR, nicotinamide riboside; PWThD, posterior 
wall thickness in diastole; PWThS, posterior wall thickness in systole; and SV, stroke volume.
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modest 5% to 7% increase in body weight in control 
mice and allowed SRFHKO mice to regain weight after an 
initial loss, whereas SRFHKO mice on a regular diet had 
lost weight at the end of the protocol (Figure 2A). Car-
diac parameters were analyzed by echocardiography 
between days 45 and 47 (Figure 2B through 2O). NR did 
not change heart rate and LV mass index, but slightly it 
increased the LV thickness-to-radius ratio (H/R) in con-
trol mice (Figure 2N). To assess a potential impact of NR 
treatment on vascular function, we compared vascular 
reactivity in isolated mesenteric arteries from NR-fed 
and control mice. We found no difference between the 
2 groups neither in responses to K+ or agonist-induced 
contraction nor in the relaxation response to carbachol 
or a NO donor (Figure I in the online-only Data Supple-
ment and Table III in the online-only Data Supplement).
SRFHKO mutant mice fed the standard diet displayed 
a severe decrease in LV ejection fraction and fraction-
al shortening (Figure  2D and 2E). The NR diet clearly 
protected against this decline in cardiac function. It is 
important to note that NR fully protected SRFHKO mice 
against the dilatation and thinning of the LV wall (Fig-
ure 2F through 2M), preserving the H/R ratio that nor-
mally declines with DCM (Figure 2N). Changes in stroke 
volume (Figure  2O) and cardiac output (not shown) 
were not significant.
At the histological level, NR limited the appearance 
of very long cardiomyocytes (Feret > 100 µm) in SRFHKO 
mice, although the population of large cardiomyocytes 
(minFeret > 26 µm) remained larger than in controls 
(Figure II in the online-only Data Supplement).
NR-Enriched Diet Protects the Cardiac 
NAD+ Metabolome in HF
The impact of an NR-enriched diet on the cardiac NAD+ 
metabolome is not known (Figure 3A). Mice fed with or 
without NR were euthanized 3 days after the echocar-
diography at day 50. Myocardial NAD was decreased 
in the SRFHKO mice at day 50 as measured by the NAD 
cycling assay, and the NR diet protected against this 
drop (Figure 3B). Myocardial NAD+ and NADH varied in 
the same direction in all conditions, leaving the NAD+/
NADH ratio unchanged (Figure III in the online-only 
Data Supplement). Liquid chromatography-mass spec-
trometry analysis allowed us to provide the levels of 
NAD+ metabolites on a common scale with NAD+13,33 
(Figure 3C through 3L). SRFHKO mice hearts did not have 
higher levels of adenosine diphosphate ribose (ADPR) 
or NAM (Figure 3D and 3E). Levels of NADP+ and NMN 
showed a pattern similar to NAD+ (Figure 3F and 3G).
NR increased the cardiac levels of nicotinic acid adenine 
dinucleotide, a sensitive biomarker of increased NAD+ 
metabolism,29 and methyl-NAM (MeNAM), as well (Fig-
ure 3A, 3H through 3J). MeNAM oxidation by AOX1 gen-
erates N1-methyl-4-pyridone-5-carboxamide (Me4PY) 
and releases hydrogen peroxide (Figure 3A). Changes in 
unrelated metabolites were not significant (Figure 3K and 
3L). As shown in the nematode,34 NR increased the ex-
pression of the Nfel2 gene encoding NRF2, whereas its 
target genes Mt2 and Nox4 were already activated, and 
G6pdx, as well, in the heart of SRFHKO mice (Figure 3M 
through 3P). NR treatment in the SRFHK0 hearts limited 
the level of Myh7 induction, a signature of cardiac stress 
and metabolic remodeling in the failing heart (Figure 3Q).
The liver is a central organ for the regulation of nu-
trient metabolism. We assessed the NAD+ metabolome 
response in the liver of control and SRFHKO mice (Table IV 
in the online-only Data Supplement). NR increased the 
MeNAM and Me4PY levels similarly in both genotypes. 
It is interesting to note that the liver response to NR 
diet was more robust in the SRFHKO mice with regard to 
the increase in the steady-state level of NAD, nicotinic 
acid adenine dinucleotide, ADPR, and NAM. Because 
the liver is not targeted by the Srf deletion, it suggests 
that the HF condition indirectly modifies the balance of 
NAD synthesis and signaling in the liver.
NR-Enriched Diet Does Not Result in 
Global Cardiac Protein Deacetylation
The cardiac levels of NAM and ADPR in this HF model 
are low and show few changes with NR (Figure 3D and 
3E), suggesting that the NR-driven boost in NAD+ syn-
thesis is not necessarily translated into a higher level 
of NAD+ consumption by sirtuins and poly(ADP-ribose) 
polymerases. We performed antiacetyl-K and anti–poly-
ADP-ribose Western blot analyses on cardiac proteins 
from control and SRFHKO mice fed with the chow diet 
or NR-enriched diets. Just as levels of ADPR were not 
modulated by SRFHKO or NR, neither were levels of PAR 
(Figure IVA in the online-only Data Supplement ). There 
was an increase in the acetylation level of some cardiac 
proteins in the hearts of NR-fed animals (Figure IVB in 
the online-only Data Supplement). Antibodies specific 
to the acetylated form of FOXO1 or p53 showed an in-
crease in the acetylation level of these nuclear proteins 
in the heart in response to NR in controls as in SRFHKO 
mice (Figure 3R, Figure V in the online-only Data Supple-
ment). By comparison, the acetylation level of the mito-
chondrial aconitase 2 protein did not change in any of 
these conditions despite lower protein level in the SRFHKO 
hearts (Figure 3S and Figure VIA in the online-only Data 
Supplement). These data suggest that the bioenergetic 
improvement in NR-supplemented hearts may result in 
greater production of cytosolic Ac-CoA and consequent 
increased nucleocytosolic protein acetylation.
NR Improves Metabolism of Citrate in HF
Several regulators involved in mitochondrial biogenesis 
and oxidative metabolism, and lipid metabolism, as 
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Figure 3. Impact of NR treatment on cardiac NAD+ metabolome. 
A, NR to NAD+ pathway and NAD+ catabolism are depicted. NAD+ is cleaved into NAM and ADP-ribose by NAD+-consuming 
enzymes. NAM is either recycled by NAMPT or methylated by the nicotinamide N-methyltransferase (NNMT) enzyme and oxi-
dized by the aldehyde deoxidase 1 (AOX1) giving rise to degradation products MeNAM and Me4PY, respectively. B, Myocardial 
NAD was quantified by colorimetric NAD+ cycling assay at day 50 in controls (n=6), Controls+NR (Continued )
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well, were repressed in SRFHKO hearts (Figure VIIA and 
VIIB in the online-only Data Supplement). Simultaneous-
ly, the expression of the glucose transporter Glut1 was 
increased and expression of Pdk2 was decreased, which 
can be seen as a trend of the failing heart to increase 
glycolysis (Figure VIIC in the online-only Data Supple-
ment). NR did not alter the expression of these genes.
There was a trend toward a reduced mitochondrial 
to genomic DNA ratio in the SRFHKO LV (Figure 3T). The 
NADH-dependent complex I activity and Cox activity 
was not changed by the NR diet (Figure 3U and 3V). 
Neither the complex I and II maximal respiration rates, 
nor the apparent Km for ADP, mitochondrial CK cou-
pling, and ADP acceptor control ratio showed any al-
teration at this stage (day 50) in the SRFHKO LV fibers. 
These parameters were not altered by NR administra-
tion (Figure VIID through VIIG in the online-only Data 
Supplement).
We noted that NR treatment resulted in a net increase 
in acetylation of FOXO1 and p53 (Figure 3R and Figure V 
in the online-only Data Supplement). Availability of cyto-
solic Ac-CoA depends on mitochondrial citrate synthase 
(CS) production of citrate and conversion to Ac-CoA via 
the cytosolic enzyme, ATP-citrate lyase (ACL). CS activity 
was reduced to 65% of control levels in the SRFHKO LV 
myocardium (Figure 3W). It is striking that NR adminis-
tration protected against the decline of CS activity in the 
failing heart. This rescue in activity occurred despite a net 
reduction in protein level in the SRFHKO myocardium that 
was not rescued by the NR treatment (Figure VIB in the 
online-only Data Supplement). It is interesting to that NR 
also increased cardiac ACL activity in both control and 
SRFHKO mice (Figure 3X). Taken together, these data sug-
gest that NR improves CS and ACL activity, resulting in 
increased nucleocytoplasmic protein acetylation.
Nmrk2 Gene Is Induced by Inhibition of 
Alternative NAD+ Biosynthetic Pathways 
in Cultured Cardiomyocytes
To assess the impact of NMRK2 on NAD+ biosynthesis 
relative to the other pathways in cardiomyocytes, we 
used chemical inhibitors to target the alternative path-
ways in neonatal rat cardiomyocytes (NRCs) grown in 
Dulbecco modified Eagle medium containing NAM as 
the vitamin B3. The glutamine analog azaserin inhibits 
the glutamine-dependent NAD synthase NADSYN1,35 
which catalyzes the last step of NAD+ synthesis from 
tryptophan and NA (Figure 1A). FK866 is a specific in-
hibitor of Nampt.36
Azaserin had a slowly repressive effect on NAD pools 
that resulted in a 50% reduction with respect to non-
treated cells at 72 hours (Figure 4A through 4C) while 
progressively increasing Nmrk2 expression (Figure 4D). 
FK866 treatment led to a rapid and severe loss of intra-
cellular NAD+ but not NADH (Figure 4A through 4C). 
Despite this severe loss, NRC could be maintained up 
to 72 hours in continuous layer with FK866 treatment. 
FK866 treatment strongly increased Nmrk2 expression 
at 72 hours (Figure 4D). Combined azaserin and FK866 
treatment had a similar impact than FK866 alone (Fig-
ure 4A through 4D). Nmrk1 expression did not change 
in these conditions (not shown).
We tested whether NR could preserve NAD+ levels 
in the presence of FK866. NR slightly increased the 
baseline level of intracellular NAD+ in nontreated NRC, 
whereas exogenous NAD+ had no impact (Figure 4E). 
Both compounds increased the NAD+/NADH ratio (Fig-
ure 4F and 4G). NR fully protected NAD+ levels in NRCs 
treated with FK866, whereas the protection by exoge-
nous NAD+ was partial (Figure 4E), although both treat-
Figure 3 Continued. (n=5), SRFHKO (n=6), SRFHKO+NR (n=6). Data are expressed as means±SEM. C through L, Myocardial me-
tabolites were analyzed by LCMS-based metabolomics. See abbreviations in the text. Controls (n=4), controls+NR (n=5), SRFHKO 
(n=6), +NR (n=5, except for NAM, MeNAM, and Me4PY, n=4, no peak was identified in 1 sample). Data are expressed as 
means±SEM. M through Q, Expression of genes related to oxidative stress signaling (M through O) and cardiac structural and 
metabolic remodeling (P and Q). n=5 in each group. R, Representative Western blot analysis of FOXO1 and acetyl-FOXO1 of 3 
independent experiments realized in different duplicates for each group. GAPDH is used as a loading control. Right graphs, 
Quantification of total and acetyl-FOXO1 ratio on GAPDH and acetyl-FOXO1/total FOXO1 ratio in n=5 to 6 animals per group. 
S, Acetylation level of mitochondrial aconitase 2. Aconitase 2 (75 kDa) was immunoprecipitated using a rabbit polyclonal 
antibody, and the immunoprecipitate was analyzed by Western blot using a mouse monoclonal anti-Ac(K103) antibody. Inputs 
were run in a parallel gel and immunoblotted with anti-aconitase 2 and anti-GAPDH for loading control. The ratio of acetyl-
aconitase2/total aconitase2 and aconitase2/GAPDH are shown (right). See accompanying Figure VIA in the online-only Data 
Supplement for control immunoprecipitation with preimmune rabbit IgG. T through X, LV cardiac tissue was isolated at 50 
days after tamoxifen injection in control and SRFHKO mice fed control diet (CD) or NR-enriched diet. DNA and proteins were 
extracted from parallel samples to quantify mitochondrial to genomic DNA ratio (T) and enzymatic activities: complex I (U), cy-
tochrome oxidase (V), citrate synthase (W), and ATP citrate lyase (X). See associated Figure VII in the online-only Data Supple-
ment. In M through S, data are expressed as mean fold change (FC)±SEM over control group CD. Statistical analysis: Two-way 
factorial ANOVA for independent samples was used for all panels. ¶P≤0.05, ¶¶P≤0.01, ¶¶¶P≤0.001 for the genotype effect; 
§P≤0.05, §§P≤0.01, §§§P≤0.001 for the NR treatment effect; ii P≤0.01 for the interaction effect. Post hoc Tukey test: asterisks 
indicate statistically significant difference versus the control CD group: **P≤0.01. ACL indicates ATP-citrate lyase; ADP, ad-
enosine diphosphate ribose; Cont, control; CS, citrate synthase; IMP, inosine monophosphate; LCMS, liquid chromatography-
mass spectrometry; NAAD, nicotinic acid adenine dinucleotide; NAD, nicotinamide adenine dinucleotide; NAM, nicotinamide; 
NAMPT, nicotinamide phosphoribosyltransferase; NMN, nicotinamide mononucleotide; and NR, nicotinamide riboside. 
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Figure 4. Nmrk2 expression is activated by repression of alternative NAD+ biosynthetic pathways. 
A through C, Intracellular levels of NAD+ (A), NADH (B), and NAD+/NADH ratio (C) in NRC after 10 µmol/L FK866 and 20 
µmol/L azaserin treatment or no treatment (NT) for 24 to 72 hours as indicated. D, Nmrk2 mRNA level in NRC treated as in 
A through C. E through G, Same as in A through C in NRC treated for 72 hours with 10 µmol/L FK866 or not treated (NT) in 
normal culture medium (–) or in presence of 250 µmol/L NAD+ or 1 mmol/L NR. H, Nmrk2 mRNA level in NRC treated as in E 
through G. I, NAD+ levels in NRCs treated with 10 µmol/L FK866 for 72 hours, or not treated (NT) in the presence of increasing 
concentration of NR in culture medium. J, NAD+ content in nontreated (NT) or following 24-hour NR treatment (1 mmol/L) in 
NRC infected with Ad-GFP or HA-Nmrk2. Right, Western blot detection of HA-NMRK2 with anti-HA antibody. K through M, 
Mitochondrial stress test in Seahorse analyzer. NRC grown on Seahorse 96-well plates were analyzed for oxygen consumption 
rate (OCR) at day 8 after 5 days of treatment. K, Basal mitochondrial respiration is calculated from total cellular respiration 
minus nonmitochondrial respiration. L, ATP production is calculated from basal mitochondrial respiration minus respiration 
after oligomycin injection. M, Maximal respiration is measured after FCCP injection. See accompanying Figure IX in the online-
only Data Supplement for other respiration parameters. N through P, Glycolysis stress test in Seahorse analyzer. NRC grown on 
Seahorse 96-well plates were analyzed at day 8 after 5 days of treatment. N, Glycolysis was measured as a function of extra-
cellular acidification rate (ECAR) after injection of 10 mmol/L glucose. O, Glycolytic capacity as the maximum ECAR following 
injection of oligomycin. P, Glycolytic reserve as the difference between glycolysis and maximal glycolytic capacity. Throughout 
the figure, data are expressed as mean fold change (FC)±SEM over the control group, except when indicated. Statistical analy-
sis: a 2-way factorial ANOVA for independent samples was used for A through J. ¶ and § symbols as indicated in the panels; 
i P≤0.05, ii P≤0.01, iii P≤0.001 for the interaction effect. One-way ANOVA was used for K through P. ¶ P<0.05, ¶¶ P<0.01, 
¶¶¶ P<0.001. §§ P≤0.01, §§§ P≤0.001. Post hoc Tukey test: *P<0.05, **P<0.01, ***P<0.001 between any (Continued )
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ments blocked Nmrk2 induction (Figure  4E). At least 
100 µmol/L NR was required to rescue the NAD+ loss 
induced by 10 µmol/L FK866 (Figure 4I). To assess the 
functionality of NMRK2 in the absence of a stress like 
the FK866, we infected NRC with a recombinant ade-
novirus expressing HA-tagged Nmrk2 cDNA (Figure 4J). 
Overexpression of NMRK2 did not modulate the NAD+ 
levels in NRC. In presence of NR, Nmrk2 overexpression 
robustly increased the NAD+ level by a factor of 6. NR 
alone slightly increased the NAD+ level in control NRC 
infected with Ad-GFP (Figure  4J). In isolated primary 
cultures of adult rat cardiomyocytes, NR increased in-
tracellular NAD nearly 3-fold, showing that the NMRK 
pathway is more active in adult rat cardiomyocytes than 
in NRCs (Figure VIIIA in the online-only Data Supple-
ment). FK866 reduced NAD levels by a factor of 2 (Fig-
ure VIIIA in the online-only Data Supplement) in adult 
rat cardiomyocytes and increased Nmrk2 expression by 
a factor of 4.5, whereas azaserin had no impact (Figure 
VIIIB in the online-only Data Supplement). We assessed 
the impact of NR on oxygen consumption rates in NRC 
following a mitochondrial stress protocol. NR had no 
impact on any mitochondrial respiration parameter in 
NRC at baseline (Figure 4K through 4M, Figure IX in the 
online-only Data Supplement). NR increased glycolysis 
at baseline in a dose-dependent manner (Figure  4N), 
but not the maximal glycolytic capacity (Figure  4O 
and 4P). We assessed the capacity of NR to rescue 
any impact of FK866 on metabolism. FK866 reduced 
basal oxygen consumption rates and maximal respira-
tion and trended to reduce ATP production (adjusted 
P value=0.0547) (Figure 4K through 4M). Addition of 
NR at doses that we showed to fully rescue the drop 
in NAD+ levels triggered by the FK866 did not correct 
these alterations and even further reduced maximal res-
piration at high doses (Figure 4K through 4M, Figure 
IX in the online-only Data Supplement). FK866 strong-
ly reduced basal glycolysis and glycolytic capacities in 
NRC. NR strikingly preserved NRC glycolytic capacities 
to 100% control levels and more in FK866-treated cells 
and stimulated glycolysis at baseline in nontreated cells 
in a dose-dependent manner (Figure 4N through 4P).
SRF Deficiency-Induced Depression of the 
Nmrk2 Promoter Is Counterbalanced by 
the Sensitivity of Nmrk2 Gene to NAD+ 
Depletion and Energetic Stress
Because Nmrk2 expression is activated in vivo on Srf 
gene inactivation, we addressed the role of the SRF tran-
scription factor in Nmrk2 gene regulation. We identified 
an SRF binding site with 9/10 bp match to the consensus 
CC(A/T)6GG (CArG) sequence in a conserved 600-bp re-
gion between the murine and human genes (Figure 5A). 
We cloned the upstream region and 5ʹ-UTR of the mu-
rine Nmrk2 gene (–581/+61) into a luciferase reporter 
vector and mutated the CArG-like sequence to a motif 
matching the consensus sequence (5ʹ-CC) or a motif un-
able to bind SRF (5ʹ-GG) (Figure 5A). FK866 increased 
the expression of the WT construct 8-fold, whereas a 
consensus CArG reduced the extent of activation (Fig-
ure 5B). The 5ʹ-GG mutation reduced baseline expression 
by 75% and abolished the response to FK866. The full 
intergenic 3009-bp sequence upstream of Nmrk2 had 
a much higher activity, especially in response to FK866 
(Figure  5C). siRNA-mediated inhibition of Srf reduced, 
but did not abolish, the induction of endogenous Nmrk2 
by FK866 in NRC, suggesting that FK866-triggered acti-
vation of the Nmrk2 promoter is partially independent 
of SRF (Figure 5D and 5E). FK866 treatment reduces ATP 
to 50% of the control level in NRC (Figure 5F). SRF is 
major upstream regulator of Ckm gene involved in high-
energy phosphate compounds balance. A siRNA-mediat-
ed 5-fold knock-down of Ckm gene expression lowered 
the cellular ATP levels to 70% control level and triggered 
a 6.8-fold increase in Nmrk2 expression (Figure 5G and 
5H). A 2-fold reduction in Srf expression resulted in a 
2-fold reduction of Ckm expression leaving Nmrk2 ex-
pression intact. Enforcing a more profound depression of 
Ckm expression in the context of Srf repression in NRC 
by cotransfection with both Srf and Ckm siRNAs resulted 
in a 2.3-fold increase in Nmrk2 expression (Figure 5H).
Nmrk2 Is Induced by the AMPK-PPARα 
Axis
In line with the previous results, we hypothesized that 
pathways related to energy failure might activate Nmrk2. 
The level of phosphorylated AMP-activated protein kinase 
α (AMPKα), the energy stress–sensing AMP-activated ki-
nase, and its target Ac-CoA carboxylase (ACC) was in-
creased at an early stage when Nmrk2 induction began 
in the SRFHKO hearts (Figure  6A and 6B). 5-Aminoimid-
azole-4-carboxamide ribonucleotide (AICAR) treatment 
stimulated AMPK phosphorylation in NRCs and increased 
NMRK2 protein level in NRCs (Figure 6C and 6D). The en-
ergetic stress induced by glucose deprivation for 24 hours 
or FK866 for 48 hours also increased the NMRK2 protein.
AICAR treatment did not modulate NAD+/NADH but 
robustly induced Nmrk2 expression (Figure 6E through 
6H). To assess whether the effect of AICAR took place at 
the level of the Nmrk2 promoter, we transfected Nmrk2-
Figure 4 Continued. group versus NT control cells; ##P<0.01, ###P<0.001 for indicated comparisons. Ad-GFP indicates 
adenovirus encoding green fluorescent protein; AZ, azaserin; FCCP, Carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone; 
FK, FK866; HA, human influenza hemagglutinin tag sequence; NAD, nicotinamide adenine dinucleotide; NRC, neonatal rat 
cardiomyocyte; and NR, nicotinamide riboside.
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luciferase constructs into NRC and treated the cells with 
AICAR. The p586-Luc, and moreover, the p3009-Luc 
reporter, was highly responsive to AICAR treatment (Fig-
ure 6I and 6J). Cotransfection of a plasmid overexpress-
ing a dominant negative isoform of AMPK efficiently 
blunted induction by AICAR (Figure 6I and 6J).
Analysis of the 5ʹ-regulatory sequences of Nmrk2 re-
vealed enrichment in putative peroxisome proliferator–
activated receptor (PPAR) binding sites (Figure 6K). The 
fragments –3009/–2552 and –1028/–228 contain most 
of the activity. By comparison, the activity of the Nmrk2 
promoter was very low in cardiac fibroblasts (Figure 6L). 
Figure 5. SRF is a component of Nmrk2 gene transcription. 
A, CArG-like binding site for SRF in the conserved region between the murine (M.m) Nmrk2 promoter and human (H.s) NMRK2 
intron 1. The CArG-like motif was mutated to a CArG consensus sequence (cons) and a CArG mutant (mut) site unable to bind 
SRF. B, Activity of p586-Firefly Luciferase construct bearing wild-type (WT), consensus (CONS), or mutated (Mut) CArG motif 
without (NT) or with FK866 treatment (10 µmol/L) in NRC. SV40-renilla luciferase was cotransfected with the Nmrk2-Firefly Luc 
constructs for normalization of transfection efficiency. Two-way factorial ANOVA for independent factors: ¶¶¶P<0.001 for con-
struct effect, §§§P<0.001 for FK effect; iii P≤0.001 for the interaction effect. Post hoc Tukey-test: *P<0.05, **P<0.01 FK versus 
NT; #P<0.05 CArG construct versus CArG wild type. C, Various lengths of the murine Nmrk2 regulatory region were inserted 
into pGL4 vector and transfected in nontreated or FK866-treated NRC. Two-way factorial ANOVA for independent factors: 
¶¶P<0.01 for construct effect, §§§P<0.001 for FK effect. D and E, Srf and Nmrk2 mRNA levels in NRC transfected with control 
scrambled siRNA (siScr) (white bars), or Srf or Nmrk2 siRNA (black bars), without (NT) or with FK866 treatment. Two-way facto-
rial ANOVA for independent factors: ¶¶P<0.01 for siRNA effect, §§§P<0.001 for FK effect. F and G, ATP levels in NRCs treated 
for 72 hours with FK866 (F) or siCkm (G). t test: *P<0.05, **P<0.01, between FK-treated cells or siCkm-transfected cells versus 
control cells or siCtneg-transfected cells, respectively. H, Srf, Ckm, and Nmrk2 mRNA level in NRC transfected for 72 hours 
with siRNAs as indicated. A 1-way ANOVA was used. ¶¶¶P≤0.001. Post hoc Tukey test: **P<0.01, between any group versus 
siCtneg-transfected control cells. Throughout the figure, data are expressed as mean±SEM over control group, fold change over 
control group (FC) except for B and C, fold change over promoterless pGL4 plasmid and H FC over siCtneg. CArG indicates 
CC(A/T)6GG; NRC, neonatal rat cardiomyocyte; siRNA, small interfering RNA; and SRF, Serum Response Factor. 
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Figure 6. Nmrk2 expression is increased by AMPK and PPARα pathways. 
A, Representative Western blot analysis of cardiac proteins in control and SRFHKO mice at day 9 using antibodies directed 
against ACC, phospho-ACC (Ser79), AMPKα, and phospho-AMPKα (Thr172). Phosphorylated and total proteins were ana-
lyzed on 2 separate gels (gel 1 and 2) and GAPDH antibody was used for loading control. B, Quantification (Continued )
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To assess the role of PPAR factors in Nmrk2 gene regula-
tion, we cotransfected NRC with the p3009-Luc report-
er and PPAR expression vectors. Only PPARα increased 
the activity of the Nmrk2 promoter in the presence of 
its agonist GW7647 (Figure 6M). The PPARα antagonist 
G6471 repressed the Nmrk2 promoter (Figure 6M) and 
blunted the activating effect of AICAR (Figure 6N). Nei-
ther the PPARβ nor the PPARγ antagonists had any effect 
on Nmrk2 promoter induction by AICAR. These results 
establish that Nmrk2 is an AMPK-PPARα–responsive 
gene that is induced by energy stress in cardiac cells.
NR Preserves Cardiac Function in the TAC 
Model
To determine whether NR treatment could be useful 
in other forms of HF, we assessed its efficiency in the 
TAC model of pressure overload cardiac hypertrophy. 
NR was administrated starting 2 days after the TAC 
or SHAM surgery. Kaplan-Meier survival curve analysis 
showed no significant difference, mainly because of a 
similar early mortality between the 2 groups within 1 
week after TAC (Figure 7A). NR treatment reduced the 
final drop in LV ejection fraction that occurred between 
the fourth and sixth week after TAC (Figure  7B and 
Table V in the online-only Data Supplement). NR did 
not attenuate the dilatation of the LV chamber and had 
only a transient effect on the thinning of the interven-
tricular septum (Figure 7C and 7D). At euthanization, 
the cardiac hypertrophy index was similar between the 
chow diet and NR groups (Figure 7E).
The TAC-induced HF resulted in a decrease of the 
myocardial NAD+ pool, which was partially preserved 
by NR, with little impact on the NAD+/NADH ratio (Fig-
ure 7F through 7H). TAC increased Nmrk2 expression 
level in the nontreated group and NR-treated group, 
whereas Nmrk1 expression remained unchanged and 
Nampt was repressed (Figure 7I through 7K). TAC re-
pressed Sirt3 expression, Sirt1 and Ckm expression 
while increasing the expression of Myh7, Anf, and Bnp 
(Figure 7L through 7Q) but NR treatment had no impact 
on gene expression.
DISCUSSION
We report that depressed NAD+ homeostasis and acti-
vation of NMRK2 kinase are early and persistent events 
in a mouse model of DCM leading to heart failure and 
that administration of NR, the substrate of NMRK2 and 
most energetically favorable NAD+ precursor, prevents 
Figure 6 Continued. of total and phosphoprotein signal from Western blot analyses. Data are normalized on GAPDH signal. 
The Phos/Total ratio is calculated from GAPDH normalized levels for each individual. n=6 for each group. Data are expressed 
as mean fold change (FC)±SEM over control group. t test: *P≤0.05, **P≤0.01, ***P≤0.001 over control group. C, NRCs were 
treated with FK866 (10 µmol/L, 72 hours, FK), AICAR (500 µmol/L, 48 hours, AIC), or grown in the absence of glucose in the 
medium (Glc 0) for 48 hours, and proteins were extracted for Western blot analyses. Representative Western blot. D, Quan-
tification on n=3 samples for each condition of NRCs treated as in C. Data are expressed as mean FC±SEM over NT group. 
*P≤0.05 over control group. E through G,  Intracellular NAD+ content (E), NADH (F), and NAD+/NADH ratio (G) in NRCs after 
24 hours of treatment with AICAR (500 µmol/L). H,  RT qPCR analysis of Nmrk2 mRNA level in NRCs treated with AICAR. t test: 
***P≤0.001 over nontreated control group. I and J, NRCs were cotransfected with Nmrk2-luciferase constructs containing 586 
(I) or 3009 base pairs (J) of upstream Nmrk2 regulatory region and a dominant negative (DN) AMPK expression vector. NRCs 
were transfected at day 3 after plating, followed by AICAR treatment (500 µmol/L) at day 4. Luciferase levels were analyzed at 
day 5. Normalized Fireflyl/Renilla values are expressed as in Figure 5B as FC±SEM over the promoterless pGL4 vector. One-way 
ANOVA: ¶¶P≤0.01, ¶¶¶P≤0.001 for treatment effect. Post hoc Tukey test: **P≤0.01, ***P≤0.001 over nontreated control 
group. ##P<0.01 for AICAR versus AICAR+AMPK-DN. K, Nmrk2 promoter deletion analysis by luciferase assay. Rectangular 
boxes show the position of the putative PPAR binding sites. Data are expressed as mean FC±SEM over the promoterless pGL4 
plasmid. One-way ANOVA: ¶¶¶P≤0.001. Post hoc Tukey test: **P≤0.01, over the promoterless pGL4 vector. ##P<0.01 for over 
the immediately shorter construct. L, Neonatal rat cardiac fibroblasts and cardiomyocyte-enriched fractions were separated 
on a discontinuous Percoll gradient. Cardiac fibroblasts were transfected with the p-228, p-581, and p-3009-FLuc constructs. 
Cardiomyocytes were transfected with the p-3009-FLuc. SV40-RLuc construct was cotransfected for normalization. Data are 
expressed as mean FC±SEM over the mean p228-FLuc activity in cardiac fibroblasts. One-way ANOVA: ¶P≤0.05. Post hoc Tukey 
test: *P≤0.05 Cardio-3009 over Fibro-30089. M, NRCs were cotransfected with the p3009-FLuc construct and the RXR expres-
sion vector and with either PPARα, PPAR β/δ, or PPARγ expression vectors. NRCs were treated 24 hours later with the agonists 
GW7647 (0.6 µmol/L), GW501516 (0.6 µmol/L), and G1929 (0.6 µmol/L), for PPARα, PPARβ/δ, and PPARγ, respectively, or with 
their respective antagonists, GW6471 (10 µmol/L), GSK3787 (2 µmol/L), or GW9662 (2 µmol/L). Data are expressed as mean 
FC±SEM over normalized luciferase levels of NRCs transfected with the p3009-FLuc construct alone (dashed line) in the same 
experiment. A 1-way ANOVA was used because each group is independent of the other (different agonists and antagonists): 
¶¶¶P≤0.001. Post hoc Tukey test: **P≤0.01 versus p3009-FLuc alone. ##P≤0.01 for comparison between agonist and antago-
nist. N, NRCs were transfected with the p3009-FLuc construct. Transfected NRCs were treated 24 hours later with the antago-
nists G6471, GSK3787, or G9662, 30 minutes before adding AICAR for a further 24-hour period. All concentrations were as in 
M. Data are expressed as mean FC±SEM over the p3009-luc construct treated with AICAR alone. One-way ANOVA: ¶P≤0.05. 
Post hoc Tukey: *P≤0.05 versus AICAR treated cells. ACC indicates acetyl-coenzyme A carboxylase; AICAR, 5-aminoimidazole-
4-carboxamide ribonucleotide; AMPK, AMP-activated protein kinase; NRC, neonatal rat cardiomyocyte; NT, nontreated cells; 
PPAR, peroxisome proliferator-activated receptor; and RT qPCR, quantitative reverse transcription polymerase chain reaction. 
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deterioration of cardiac function and adverse remodel-
ing (Figure 8).
Altered NAD+ homeostasis has been reported in sev-
eral models of HF including pressure overload, myocardial 
infarction, and angiotensin 2 infusion.3,37,38 In this con-
text, much attention has focused on the NAMPT enzyme 
that is repressed in several models of cardiac injuries.38 
On the other hand, we found a robust upregulation of 
Nmrk2 expression in the heart of SRFHKO developing DCM 
and a more modest but significant increase following 
TAC-induced HF. It is interesting that we observed a simi-
lar shift from repressed NAMPT to increased NMRK2 in 
human failing heart. Interrogation of the Gene Expres-
sion Omnibus (GEO) database reveals that Nmrk2 is in-
duced in several models of cardiomyopathy related to 
mutations in the lamin-A (GEO data set GDS2746),39 Idh2 
(GDS4893),40 PGC1α (GDS4776),41 or Tfr1 (GSE68745)42 
genes. Considering the relative heterogeneity of molecu-
lar functions encoded by these genes, we propose that 
the activation of the NMRK2 pathway represents a com-
mon adaptive mechanism in the failing heart. Here, we 
show that the Nmrk2 gene can be activated in response to 
NAMPT inhibition and activation of the energy stress sen-
sor AMPK. In NRCs, we show that this activation depends 
on PPARα. PPARα is often expressed at lower levels in the 
adult failing heart,43 whereas AMPK was shown to acti-
vate PPARα in various contexts.44 Hence, AMPK activation 
could compensate in part for the lower levels of PPARα to 
activate Nmrk2. The precise contribution of these actors 
in the adult failing heart remains an open question. In the 
case of SRFHKO hearts, it is interesting to note that, de-
spite the fact that SRF is an upstream regulator of Nrmk2 
gene that we would expect to be repressed following Srf 
gene inactivation, SRF is also a major upstream regulator 
of Ckm gene, which is important to maintain PCr/ADP/
ATP balance,15,18 and AMPK is activated early on in the 
SRFHKO heart (this study). We show in vitro that Ckm de-
pression alone is sufficient to induce Nmrk2 expression. 
In addition Srf inactivation alters the expression of numer-
ous sarcomeric genes and triggers a severe eccentric re-
modeling15 that is likely to further increase the energetic 
cost of contraction in vivo. A similar phenomenon could 
Figure 7. NR treatment preserves myocardial NAD 
levels and limits the drop in ejection fraction in the 
pressure overload–induced hypertrophy model. 
Two-month-old control and SRFHKO male mice were subjected 
to TAC or SHAM surgery and fed with control chow diet 
(CD) or NR-enriched diet from day 2 after surgery to day 42. 
A, Kaplan-Meier survival curve analysis. Log-rank statistic: 
P>0.05. Color code shown on the right for each group 
is valid for A through E. B through D, Echocardiography 
follow-up analysis from baseline (2 days before surgery) to 6 
weeks after. E, Heart weight to body weight ratio after euth-
anization at 6 weeks. F through H, Cardiac NAD+ and NADH 
levels and redox state assessed by the NAD+ cycling assay. 
I through Q, Cardiac mRNA levels of the indicated genes 
assessed by RT-qPCR. Data are expressed as mean±SEM. 
Statistical analysis: 2-way ANOVA for independent factors 
statistical analysis is shown at (Continued )
Figure 7 Continued. 6 weeks and was used for B through 
Q, followed by post hoc Tukey test. ¶¶P≤0.01, ¶¶¶P≤0.001 
for the TAC effect; §§§P≤0.001 for the NR treatment effect; 
i P≤0.05 for the interaction effect. Asterisks indicate statisti-
cally significant difference for the indicated comparisons: 
*P≤0.05, **P≤0.01. #P≤0.05 for the effect of NR within 
the TAC group. See accompanying Table V in the online-
only Data Supplement for other echocardiography data at 6 
weeks and previous stages. IVSThD indicates interventricular 
septum thickness in diastole; LVEDD, left ventricle end-
diastolic diameter; LVEF, left ventricle ejection fraction; NAD, 
nicotinamide adenine dinucleotide; NR, nicotinamide ribo-
side; RT-qPCR, quantitative reverse transcription polymerase 
chain reaction; and TAC, transverse aorta constriction.
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occur for instance in the lamin-A mutants, which display 
severe alterations in cardiomyocyte cytoskeletal integrity 
and in which SRF activity is repressed and Nmrk2 expres-
sion induced.22,39 In addition to its well-known roles in 
stimulating fuel oxidation to restore ATP levels, we show 
that AMPK stimulation induces Nmrk2 expression. NMN 
synthesis from NR by NMRK enzymes requires a single 
ATP, whereas synthesis from NAM by NAMPT requires 
>3 ATP equivalents: one for the autophosphorylation of 
the enzyme, and 2 (plus a carbohydrate) in formation of 
phosphoribosyl pyrophosphate  (Figure  8). Both path-
ways consume an additional ATP for fusion with NMN to 
generate the dinucleotide. Hence, the shift from NAMPT 
to NMRK2 for NAD+ synthesis is an energy-sparing mech-
anism that may be favored in HF. In turn, we show that 
one of the beneficial actions of NR, at least in vitro, may 
be to increase glycolysis in cardiomyocytes. These differ-
ent mechanisms of action may contribute to increase car-
diac efficiency, which should be assessed in future studies 
to establish whether metabolic substrate preference and 
potentially glucose oxidation, which is associated with a 
better respiratory quotient and ATP availability, are im-
proved on NR treatment.
Although the NMRK2 pathway is activated in the fail-
ing heart of SRFHKO mice, the myocardial NAD+ level is 
depressed, which suggests that circulating and tissue 
levels of NAD+ precursors are insufficient to sustain car-
diac NAD+ synthesis in mice on a regular rodent diet, 
stimulating an interest in NR supplementation to correct 
this defect. A few studies have shown that short-term 
NAD+ supplementation following chronic angiotensin-2 
administration37 or NMN supplementation following 
ischemia-reperfusion injury45 or TAC surgery46 can nor-
malize alterations in NAD+/NADH ratio in the mouse fail-
ing heart. It is interesting to note that cells do not take 
up NMN intact, and, instead, NMN is extracellularly de-
phosphorylated to NR, such that its cellular conversion 
to NAD+ depends on the NR kinase pathway.47,48
We discovered a strongly beneficial effect of NR in 
the SRFHKO model of HF in the preservation of cardiac 
function and limitation of cardiac remodeling that was 
associated with the maintenance of NAD+ levels in the 
heart. NAD+ metabolomics and expression analysis 
showed no evidence for increased levels of PAR, ADPR, 
Nam, or PARylated proteins, which would indicate a 
storm of NAD+-consuming activities in this model of 
Figure 8. Activation of the NMRK2 pathway to NAD+ synthesis as an adaptive energy-sparing mechanism in the 
failing heart. 
DCM is a form of pathological cardiac remodeling that is associated with severe energy depletion leading to HF. The energy 
stress sensor AMP-kinase is an adaptive signaling pathway aiming to preserve energy in the cells. The NAMPT enzyme is a ma-
jor, rate-limiting step for NAD+ synthesis whose energetic cost equals 4 ATP molecules, including 1 converted to AMP, for the 
synthesis of 1 NAD+. NAMPT is repressed in most forms of HF through an unknown regulatory mechanism. Opposite to this re-
pression, Nmrk2 gene is an AMPK-responsive gene that is activated in several models of DCM and other forms of pathological 
remodeling such as the pressure-overload cardiac hypertrophy. NMR-kinase 2 allows the synthesis of NAD+ at a lower cost of 2 
ATP per molecule. Although NR content may be limited in rodent and human diet, NR can easily be provided as a nutraceutical 
to help the failing heart to maintain NAD+ levels. AMPK indicates AMP-activated protein kinase; DCM, dilated cardiomyopathy; 
HF, heart failure; NAD, nicotinamide adenine dinucleotide; NAM, nicotinamide; NAMPT, nicotinamide phosphoribosyltrans-
ferase; NMN, nicotinamide mononucleotide; NR, nicotinamide riboside; PPAR, peroxisome proliferator-activated receptor; and 
PRPP, phosphoribosyl pyrophosphate. 
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HF. Instead, a progressive loss of Nampt expression, 
coupled with the known depression of ATP and high-
energy phosphates, is postulated to make it challenging 
for damaged hearts to maintain NAD+ homeostasis.
Beyond the repletion in myocardial NAD+ levels, the 
most striking NR-reversible deficit we found in HF was 
depression of CS and ACL activity. Many regulatory pro-
cesses from gene expression to enzyme activity are con-
trolled by reversible protein Lys acetylation. Although 
there is a variety of acetylases and deacetylases that are 
NAD+-dependent and NAD+-independent, production 
of citrate in mitochondria and its conversion to cyto-
solic Ac-CoA by the ACL is required to drive changes in 
substrate fuel selection2 and protein acetylation level.8,49 
NR had no impact on the acetylation level of a mito-
chondrial protein like Aco2 but robustly increased the 
acetylation level of FOXO1 or p53 transcription factors 
in SRFHKO hearts and control hearts, suggesting a tight 
link between NR-derived NAD+ synthesis and Ac-CoA 
availability for posttranslational acetylation of nucleocy-
tosolic proteins. This apparently overrides the ability of 
SIRT1 to deacetylate these factors. At the present stage, 
it is difficult to assess the consequences of these modifi-
cations. Moreover, there is presently no reason to think 
that FOXO1 and p53 are the only targets whose acetyla-
tion level is modified by long-term NR treatment. Rather, 
our data suggest that the acetylation levels of FOXO1 
and p53 can be considered as surrogate markers of an 
increase in nucleocytosolic Ac-CoA metabolism.
Last, we observed that NR led to heightened produc-
tion of Me4PY, a terminal NAM metabolite associated 
with local production of H2O2. This pathway was shown 
to promote life extension in the Caenorhabditis elegans 
through a hormetic response to a moderate rise in reac-
tive oxygen species, which activates the cytoprotective 
NRF-2 transcription factor involved in oxidative stress 
response.34 In the SRFHKO heart, NR was shown to result 
in Me4PY simultaneous with induction of NRF-2.
Here, we also show a modest although significant 
protective effect of NR treatment on the drop of LV ejec-
tion fraction observed in the TAC model. The effect of 
NR in the TAC model seems to be less important than in 
the DCM model, which may be linked to the different 
nature of the cardiac stress in these models, ie, pressure 
overload in the TAC model that increases afterload ver-
sus volume overload in DCM that increases preload, and 
the fact that the Nmrk2 gene is less strongly induced 
in the TAC model than in the SRFHKO model. We note 
also that the early mortality induced by the TAC led to 
an early dropout in the untreated and NR-treated TAC 
groups that may have introduced a bias by removing 
from the analysis the animals with the worst outcome.
In conclusion, our work shows that oral NR supple-
mentation is a powerful approach to preserve cardiac 
function and limit remodeling in DCM, a devastating 
disease currently lacking effective therapies. Recently, 
mutations in the de novo NAD+ biosynthetic pathway 
were shown to lead to a new category of genetic dis-
eases called congenital NAD deficiency disorders, which 
are associated with cardiac and skeletal defects but cor-
rectible by niacin supplementation in mouse models of 
the disease.50 Our study and previous findings by oth-
ers13,26–28 suggest that NR has the potential not only to 
improve the cardiac symptoms in congenital syndromes 
and acquired HF, but also to act at a systemic level nota-
bly on liver metabolism, insulin resistance, and skeletal 
muscle performances that are altered concomitantly 
with cardiac defects. However, a limitation of our study 
is the fact that we did not study the impact of NR on 
the survival rate of SRFHKO mice and the occurrence of 
terminal congestive HF. Further work will be required to 
determine the pharmacokinetics and pharmacodynam-
ics of therapeutic NR administration in animal models 
and people with HF to enable safe and effective human 
translation.
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CORRECTION
Correction to: Nicotinamide Riboside 
Preserves Cardiac Function in a Mouse 
Model of Dilated Cardiomyopathy
In the article by Diguet et al, “Nicotinamide Riboside Preserves Cardiac Func-
tion in a Mouse Model of Dilated Cardiomyopathy,” which published ahead of 
print December 7, 2017, and appears in this issue of the journal (Circulation. 
2018;137:2256-2273. DOI: 10.1161/CIRCULATIONAHA.116.026099), the follow-
ing corrections were made.
Figure 3S of the preprint online version contained a picture of an anti-aconitase 
2 immunoblot (blot 2) that was performed after stripping of the acetyl-lysine an-
tibody used to label immunoprecipitated aconitase 2 (blot1). As the efficiency of 
the stripping procedure could not be guaranteed, the picture of blot 2 has been 
removed. Instead, a picture of the input proteins used for immunoprecipitation 
that were run at the same time in a parallel gel is shown, as well as an immunob-
lot for GAPDH for loading control (previously Supp. Figure S6A). The picture of 
blot 1 has also been enlarged to show that a single acetylated protein migrating 
as the same size than aconitase 2 is present in this region of the gel. A picture of 
control IgG immunoprecipitation of cardiac proteins followed by anti-Acetyl-Lysine 
immnunoblot showing the absence of non specific acetylated band in this region 
of the gel is now shown in a new Figure VIA in the online-only Data Supplement.
© 2018 American Heart Association, Inc.
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SUPPLEMENTAL	MATERIAL		
Supplemental	Methods		
Transgenic	mice	All	experiments	with	animals	conformed	to	the	Directive	2010/63/EU	of	the	European	Parliament	and	were	approved	by	the	ethics	committee	Charles	Darvin	#5	(agreement	00369.01).	SRFHKO	mice	bear	the	tamoxifen-inducible	α-MHC-MerCreMer	transgene	and	the	 Srf	 floxed	 allele	 (Sf/Sf)	 as	 described	 previously.1	 Tamoxifen	 (Sigma	 T5648)	 was	administrated	by	i.p.	injection	at	a	dose	of	0.7	mg	diluted	in	100	μl	peanut	oil	at	D0,	D1	and	D2	to	SRFHKO	mice	and	Sf/Sf	control	littermates	at	9	month	of	age.	The	sex	ratio	was	balanced	in	each	group.	For	phenylephrine	administration,	the	series	of	mice	treated	with	PE,	80	mg/kg/day	for	15	 days	 with	 Alzet	 osmotic	 micropumps	 and	 the	 impact	 of	 the	 treatment	 on	 cardiac	parameters	 have	 been	 published	 previously.2	 TAC	 surgery	 was	 performed	 under	ketamine/xylazine	anesthesia.	Briefly	 the	upper	 cartilage	of	 the	 sternum	was	open	on	less	 that	 0.3	 cm	 to	 get	 access	 to	 the	 aortic	 cross	 without	 requirement	 for	 artificial	ventilation	of	the	mice.	A	27-Gauge	needle	was	plied	along	the	aortic	cross	between	the	branching	 of	 the	 right	 brachio-cephalic	 artery	 and	 the	 left	 carotid	 artery	 and	 2	 tight	knots	with	a	6.0	suture	were	made	around	the	aortic	cross	and	the	needle.	The	needle	was	quickly	removed	to	allow	the	blood	to	go	through	and	the	skin	sutured	with	4.0	silk.	Mice	 were	 administrated	 buprenorphine	 for	 the	 first	 24h	 and	 monitored	 daily	 by	trained	staff	to	detect	signs	of	pains	or	issues	with	the	suture.	Animal	showing	signs	of	prostration,	and/or	infections	and/or	inability	to	feed	by	themselves	were	sacrificed	for	ethical	reasons.		
NR	supplementation	The	 soft	 pellets	 were	 prepared	 every	 5	 days	 by	 mixing	 1.65	 g	 of	 NR	 into	 500	 g	 of	powdered	SAFE	A04	diet	and	235	ml	of	water	to	reach	2.24	mg	of	NR	/	g	(wet	weight).	Control	diet	was	prepared	in	the	same	way	omitting	NR.	Mice	had	ad	libitum	access	to	food	and	water.	Mice	(average	body	weight	31.3	±	0.82	g,	no	difference	between	groups)	consumed	an	average	of	6	g	of	soft	food	per	day,	reaching	a	minimal	daily	intake	of	450	mg	NR/kg.	No	difference	in	food	intake	was	observed	between	SRFHKO	and	control	mice.	For	NAM	and	NR	i.p.	administration,	mice	were	injected	daily	at	a	dose	of	1	μmole/	g	body	weight	with	300	mM	NAM	or	NR	solution	in	saline.		
Microarray	and	RT-PCR	analysis	To	evaluate	the	effects	of	SRF	deletion	on	gene	expression,	total	RNA	was	purified	from	
SRFHKO	 and	 control	 Srffl/fl	 hearts	 with	 the	 RNeasy	 fibrous	 tissue	 kit	 (Qiagen).	 We	examined	 the	 effects	 of	 SRF	 inactivation	 on	 gene	 expression	 at	 8	 days	 after	 TAM	injection,	an	early	stage	when	SRF	is	already	strongly	diminished	but	cardiac	functions	are	not	altered	and	at	25	days	after	TAM	injection,	an	intermediate	stage	when	the	LVEF	starts	to	decrease	and	LV	chamber	begin	to	dilate.1	In	addition,	we	compared	the	effect	of	 phenylephrine	 (PE),	 an	 alpha-adrenergic	 agonist	 known	 to	 trigger	 cardiac	hypertrophy,	administrated	at	80	mg/kg/day	with	Alzet	osmotic	minipumps	from	day	5	to	15	after	TAM	injection	to	SRFHKO	and	control	Srffl/fl	as	previously	described.		
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Microarray	 analysis	 for	 each	 genotype	was	 performed	 with	 four	 samples,	 each	 being	hybridized	to	one	Affymetrix	GeneChip	MOE	430	2.0	array	(Affymetrix,	Santa	Clara,	CA)	with	 a	 coverage	of	45,000	 transcripts,	corresponding	 to	over	30,000	mouse	 genes.	All	technical	microarray	procedures	were	carried	out	by	PartnerChip	(Evry,	France)	under	Affymetrix	guidelines.	Briefly,	2	μg	of	total	RNA	sample	was	used	to	synthesize	double	stranded	cDNA	with	the	SuperScript	II	double-stranded	cDNA	synthesis	kit	(Invitrogen	Life	Technologies,	 Carlsbad,	CA)	according	 to	 the	manufacturer's	 instructions.	 Labeled	cRNA	was	synthesized	using	the	Affymetrix	IVT	amplification	and	labeling	kit.	20	μg	of	purified,	fragmented	labeled	cRNA	were	hybridized	with	an	array	at	45°C	for	16	h	in	an	Affymetrix	640	hybridization	oven.	The	posthybridization	process	was	performed	in	an	Affymetrix	 Fluidics	 Station	 450	according	 to	 the	manufacturer's	 instructions.	 All	 gene	chips	were	scanned	on	an	Affymetrix	GeneChip	3000	scanner,	and	data	were	extracted	from	 scanned	 images	 using	 AFX	 GCOS	 1.4	 software.	 Background	 intensities	 were	adjusted	and	normalized	using	GCRMA	method	implemented	in	R	(version	2.4.1).		
RT-qPCR	cDNAs	were	reverse	transcribed	from	RNA	(1.5	μg)	extracted	in	TRIzol	(Thermofisher)	from	 cell	 cultures	 and	 tissues	 using	 the	 Superscript	 II	 Reverse	 Transcriptase	 (Life	Technologies).	 Quantitative	 PCR	 was	 carried	 out	 on	 a	 Light	 Cycler	 480	 (Roche	Diagnostics)	using	Fast	Start	SYBR	Green	Master	(Roche	Diagnostics).	Quantification	of	gene	expression	was	calculated	as	R=2ΔCt(Ref	Cp	–	target	Cp)	,	with	Hprt	used	as	a	as	reference.	 Primers	 were	 designed	 using	 the	 NCBI	 Primer-BLAST	 software.	 Primer	sequences	are	available	on	request.		
Western	Blot	Analysis	Proteins	were	homogenized	 in	a	 lysis	buffer	 (Tris-HCl	pH7.5	50	mM,	NP40	 Igepal	1%,	NaCl,	 150	 mM,	 EDTA	 1mM,	 DTT	 1mM,	 Glycerol	 10%)	 in	 the	 presence	 of	 proteases.	phosphatases	 and	 deacetylases	 inhibitors	 (PMSF	 0.5	 mM,	 NaF	 50	 mM,	 PPiNa	 5	 mM,	Roche	 protease	 cocktail	 inhibitor	 1/100,	 Santa	 Cruz	 deacetylase	 cocktail	 inhibitor	1/100).	 Equal	 amounts	 of	 proteins	 (10	 to	 20	μg)	 were	 separated	 on	 SDS-PAGE	 and	transferred	 to	 nitrocellulose	 membranes.	 Proteins	 were	 detected	 by	 overnight	incubation	 at	 4°C	 with	 primary	 antibodies	 followed	 by	 IRDye	 700	 or	 IRDye800	fluorescent	 antibodies	 (Li-Cor	 Biosciences.	 1/2500)	 and	 scanned	 on	 an	 Odyssey	 CLx	Infrared	 Imaging	 System	 (Li-Cor	 Biosciences).	 Acetyl-CoA	 Carboxylase	 (ACC):	Thermoscientific	#	MA5-15025;	dilution	1/1000.	ACC	Phospho-Ser79:	Thermoscientific	#	PA5-17725;	dilution	1/1000.	Acetylated-Lysine	Mouse	mAb	(Ac-K-103)	:	Cell	Signaling	#9681	;	 dilution	 1/1000.	 AMPKα:	 Cell	 Signaling	 #2532;	 dilution	 1/1000.	 AMPKα	(Phospho-Thr172):	Cell	Signaling	#2535;	dilution	1/1000.	FKHR	(H-128)(FoxO1):	Santa	Cruz	 BT	 #	 sc-11350;	 dilution	 1/1000.	 AcFKHR	 (D-19):	 Santa	 Cruz	 BT	 #	 sc-49437;	dilution	1/200.	Acetyl-Lysine:	Cell	Signaling	#9441;	dilution	1/1000.	Citrate	Synthase:	Abcam.	GAPDH:	 Sigma	#G9545;	dilution	1/3000.	Aconitase	2:	Kind	gift	 of	Anne	Laure	Bulteau	 (Bulteau	 et	 al.	 Biochemistry.	 2003;42(50):14846-55);	 dilution	 1/500.	 HA	epitope:	 Sigma	#H6908;	 dilution	 1/500.	 NMRK2:	 generated	 by	 BioGenes	 (see	 below);	dilution	 1/500.	 PARP:	 Cell	 Signaling	 #9532;	 dilution	 1/1000.	 PAR	 (Anti-Poly	 (ADP-Ribose):	 Pharmingen	 #551813	 dilution	 1/500.	 p53	 (acetyl	 K386):	 Abcam	 #ab52172;	1/500.	Anti-Visfatin	antibody	(NAMPT)	:	Abcam	#ab24149	;	1/500.		
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Generation	of	rabbit	polyclonal	antibody	against	NMRK2	protein	Polyclonal	 antibody	 was	 generated	 in	 rabbits,	 immunized	 with	 a	 peptide	 sequence	specific	 to	 the	 NMRK2	 protein,	 verified	 and	 affinity	 purified	 and	 tested	 by	 BioGenes	GmbH	 (Berlin,	 Germany).	 SDS-PAGE	 analysis	 using	 the	 NMRK2	 antibody	 on	 cardiac	muscle	 lysates	 was	 performed	 on	 membranes	 blocked	 with	 5%	 milk	 using	 a	 1/500	dilution,	 with	 a	 rabbit	 HRP	 secondary	 that	 was	 used	 at	 a	 1/25,000	 dilution	 and	developed	using	a	chemoluminescence.		
Immunofluorescent	staining	Hearts	were	harvested	after	cervical	dislocation	and	washed	in	cold	PBS.	Frozen	hearts	section	(10	μm)	were	fixed	in	3.7%	formaldehyde	in	PBS	at	room	temperature	(RT)	for	10	minutes	 followed	 by	 permeabilization	 in	 PBS/Triton	 X100	 (0.2%)	 for	 10	minutes.	Endogenous	 mouse	 immunoglobulins	 were	 blocked	 by	 1h.	 RT.	 incubation	 with	monovalent	 anti-mouse	 IgG	 Fab	 fragments	 (Jackson	 Immunoresearch)	 followed	 by	saturation	of	non-specific	binding	sites	with	2%	BAS	and	10%	goat	serum.	Sections	were	incubated	 o/n	 at	 4°C	 with	 mouse	 monoclonal	 [clone	 5B4.7]	 (IgG1)	 to	 human	 MIBP	(=NMRK2)	 at	 1/100	 dilution	 in	 saturation	 solution	 (LSBio,	 Seattle,	 USA	 and	 kind	 gift	from	 Dr	 Chuanyue	 Wu,	 University	 of	 Pittsburgh,	 USA).	 The	 day	 after,	 sections	 were	incubated	 with	 FITC-coupled	 anti-hVIN-1vinculin	 antibody	 (Sigma.	 1/100)	 and	 Cy3-couple	 antimouse	 IgG1	 (Jackson	 Immunoresearch.	 1/400).	 Confocal	 images	 were	acquired	 on	 a	 Leica	 SP5	microscope	with	 identical	 gain	 and	 offset	 parameters	 for	 all	samples.		
Echocardiography	Echocardiography	 was	 performed	 on	 lightly	 anesthetized	 mice	 given	 isoflurane	(induction	with	1%	 isoflurane	100%	O2	and	maintained	with	0.2	 to	0.25%	 isoflurane	100%	 O2)	 to	 maintain	 high	 cardiac	 frequency.	 Non-invasive	 measurements	 of	 left	ventricular	 dimensions	 were	 evaluated	 using	 Doppler	 echocardiography	 (Vivid	 7	Dimension/Vivid7	PRO;	GE	Medical	Systems)	with	a	probe	ultrasound	frequency	range	of	9−14	MHz.	The	two-dimensionally	guided	time-motion	recording	mode	(parasternal	long-axis	view)	of	the	left	ventricle	(LV)	provided	the	following	measurements:	diastolic	and	systolic	septal	 (IVS)	and	posterior	wall	 thicknesses	 (LVPW);	 internal	end-diastolic	(LVEDD)	and	end-systolic	diameters	(LVESD);	and	heart	rate.	Each	set	of	measurements	was	 obtained	 from	 the	 same	 cardiac	 cycle.	 At	 least	 3	 sets	 of	 measurements	 were	obtained	 from	 3	 different	 cardiac	 cycles.	 LV	 fractional	 shortening	 (FS)	was	 calculated	using	 the	 formula:	 (LVEDD	 –	 LVESD)/LVEDD	×	 100.	 LV	myocardial	 volume	 (LVV),	 LV	end-diastolic	volume	(EDV),	and	end-systolic	volume	(ESV)	were	calculated	using	a	half-ellipsoid	model	of	the	LV.	From	these	volumes,	LV	ejection	fraction	(EF)	was	calculated	using	 the	 formula:	 (EDV	–	ESV)	/	EDV	×	100.	H/R	ratio	was	calculated	by	 the	 formula	(PWThd	 +	 IVSThd)/	 LVEDd.	 A	 “blinded”	 echocardiographer,	 unaware	 of	 the	 genotype	and	the	treatment,	performed	the	examinations.		
NAD	extraction	and	quantification	Frozen	 tissue	 powder	 was	 resuspended	 in	 75%	 ethanol,	 25%	 HEPES	 10	 mM	 pH7.1,	buffer	(20	μl/mg	of	tissue).	Extracts	were	warmed	5	min	at	80°C,	then	directly	cold	on	ice	and	centrifuge	5	min	at	16	000	g.	Tissues	extracts	were	normalized	on	the	weight	of	tissue	used	for	extraction.	NAD	was	extremely	stable	in	this	buffer	and	resistant	to	heat	degradation	over	60	minutes.	Using	spiking	concentrations	of	known	amounts	of	NAD+	
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and	NADH	 (Sigma-Aldrich)	 in	 pure	 buffered	 ethanol	 solution	 followed	 by	 dilutions	 in	acid	 (HCl	 0.1M)	 or	 basic	 (NaOH	 0.1M)	 buffer,	 heating	 at	 60°C	 for	 30	 minutes	 and	neutralization	with	TRIS	buffer	pH7.1,	we	found	that	NAD+	was	extremely	stable	after	heating	in	acid	condition	(>99%	recovery)	while	NADH	was	completely	destroyed	(<1%	recovery).	Heating	in	NaOH	buffer	led	to	some	destruction	of	both	NAD+	and	NADH	and	this	protocol	was	discontinued.	Hence,	we	selected	the	protocol	of	selective	acid-heating	destruction	of	NADH	in	the	cardiac	samples	for	the	determination	of	free	NAD+	versus	free	NADH	concentrations	in	these	extracts,	 the	buffered	ethanol	extracts	were	diluted	1/10	in	HCl	0.1M	and	heated	30	minutes	at	60°C	to	destroy	NADH	and	then	neutralized	with	Tris	buffer	at	pH	7.1	before	measuring	NAD+.	After	adjustment	of	dilution	factors,	NADH	levels	were	calculated	by	subtracting	the	NAD+	concentration	to	the	non-heated	ethanolic	 extract	 values:	 NADH	 =	 NADt	 (non-heated)	 -	 NAD+(heated).	 Kinetics	 of	 the	reaction	 (OD	 at	 550nm,	 every	 30	 seconds	 for	 40	minutes)	was	 followed	 on	 a	 TECAN	Infinite	F500	microplate	 reader.	NAD	was	quantified	 in	duplicates	 for	 each	 sample	by	comparison	 to	 a	 range	 of	 standard	NAD+	 concentration	 using	 linear	 regression	 curve	equation	method	between	NAD+	standard	concentrations	and	the	slope	of	the	reaction	in	OD	units/sec.	For	cell	cultures,	the	wells	were	washed	twice	with	PBS	and	scraped	on	ice	 in	buffered	ethanol	(100μl/well	 in	12-well	plates	or	50μl/well	 in	24-well	plates).	Extracts	were	diluted	in	water	to	a	final	volume	of	25	μl	to	reach	a	concentration	that	within	 the	 titration	 curve.	We	added	100	μL	of	 reaction	buffer	 (600	mM	ethanol,	 0.5	mM	 3-(4.5-dimethylthiazol-2-yl)-2.5-diphenyltetrazolium	 bromide	 (MTT),	 2	 mM	phenazine	 ethosulfate	 (PES),	 120	 mM	 Bicine	 (pH7.8),	 yeast	 alcohol	 dehydrogenase	(SIGMA	A3263	>	300	u/mg)	0.05	mg/ml.	Kinetics	of	the	reaction	(OD	at	550nm,	every	30	seconds	for	40	minutes)	was	followed	on	a	TECAN	Infinite	F500	microplate	reader.	NAD	was	quantified	in	duplicates	for	each	sample	by	comparison	to	a	range	of	standard	NAD+	 concentration	 using	 linear	 regression	 curve	 equation	 method	 between	 NAD+	standard	concentrations	and	the	slope	of	the	reaction	in	OD	units/sec.	NAD+/NADH	was	obtained	 by	 the	 formula	 ([NADt]-[NADH])/	 [NADH].	 Proteins	 could	 not	 be	 reliably	quantified	 after	 extraction	 by	 boiling	 buffered	 ethanol	 method	 but	 cells	 layers	 were	confluent	in	all	conditions.	Hence,	in	neonatal	rat	cardiomyocytes	where	the	number	of	cells	 have	 changes	 over	 the	 culture	 period,	 data	 are	 given	 as	 fold	 change	 over	 mean	control	values	(untreated	group)	at	 the	time	of	extraction.	 In	adult	rat	cardiomyocytes	that	 do	 not	 proliferate,	 20,000	 cells	 were	 seeded	 per	 well	 in	 24-well	 plates	 and	 an	average	cylinder	volume	of	20	μm	diameter	and	100	μm	length	was	used	to	estimate	the	cellular	volume	and	calculate	the	concentration.			
Isolation	and	treatments	of	neonatal	and	adult	rat	cardiomyocytes	(NRC,	ARC)	NRC	 were	 isolated	 as	 described	 previously.3	 1-day-old	 rat	 pups	 were	 killed	 by	decapitation	and	the	cardiac	ventricles	were	harvested	and	minced	into	1	to	2-mm	wide	cubes	with	scissors.	After	washing	with	Tyrode	solution,	heart	fragments	were	subjected	up	to	10	rounds	of	digestion	with	0.05	mg/ml	of	Liberase	Blendzyme	4	(Roche	Applied	Science)	 in	10	ml	oxygenated	Tyrode	 solution	under	agitation	at	37°C	 for	10	minutes.	The	supernatant	of	the	first	digestion	was	discarded	and	the	following	digestions	were	centrifuged	 and	 the	 cell	 pellet	 dissociated	 in	 2	 ml	 of	 DMEM,	 10%	 FCS.	 The	 different	fractions	 were	 pooled	 and	 centrifuged	 on	 a	 discontinuous	 Percoll	 gradient	 (bottom	58.5%.	 top	 40.5%.	 30	 min.	 3000	 rpm)	 to	 enrich	 in	 cardiomyocytes	 at	 the	 interface	between	the	2	Percoll	solutions.	Non	cardiac	cells	containing	mainly	fibroblasts	were	at	the	 top	 of	 the	 tubes.	 Neonatal	 cardiomyocytes	 were	 seeded	 at	 a	 density	 5	 ×	 105	
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cells/well	in	6-well	plates	coated	with	10	μg/ml	of	laminin	(BD	Biosciences)	in	DMEM	without	pyruvate,	with	glucose	4.5g/l,	10%	horse	serum,	5%	FCS	and	cultured	at	37	°C	in	1%	CO2	atmosphere.	To	assay	the	impact	on	NAD+	and	Nmrk2	expression,	Azaserin	and	FK866	drugs	were	added	 in	 the	 culture	medium	at	day	5	and	 renewed	every	day	when	the	treatment	was	prolonged	over	several	days.	The	same	was	done	for	NAD+,	NR	and	 AICAR	 (5-aminoimidazole-4-carboxamide-1-β -D-ribofuranoside).	 AICAR	 was	administrated	 for	 24h	 only.	 Doses	 are	 indicated	 in	 the	 legends.	 For	 treatment	 of	transfected	 cells	 (see	 next	 section),	 AICAR,	 FK866	 and	 PPAR	 agonists	 and	 antagonist	were	 administrated	 1	 day	 after	 transfection.	 PPAR	 agonists:	 GW7647	 for	 PPARα,	GW501516	for	PPARβ/δ	and	GW1929	for	PPARγ;	PPAR	antagonists:	GW6471	PPAR
α,	 GSK3787	 for	 PPARβ/δ	 and	 GW9662	 for	 PPARγ	 were	 ordered	 from	 SIGMA	ALDRICH	CHIMIE,	Saint	Quentin	Fallavier,	France.	Adult	rat	cardiomyocytes	(ARC)	were	isolated	 as	 previously	 described.2	 ARC	 were	 seeded	 at	 20,000	 cells/well	 in	 24-well	plates	and	treated	2	hours	after	Ca2+	introduction	and	plating	with	10	μM	FK866,	20	μM	Azaserin	or	1	mM	NR	for	65h	before	NAD	extraction.	In	all	conditions,	they	were	still	more	than	60%	of	rod-shaped	cardiomyocytes	after	65	h	cultures.	The	treatment	did	not	induce	changes	in	cell	shape	or	cell	numbers.		
Seahorse	analyses	NRC	were	 seeded	at	60	000	cells/well	 in	96-well	 Seahorse	plates.	At	day	3	of	 culture,	FK866	 (10	μM)	 and/or	 a	 range	 NR	 doses	was	 added	 to	 the	medium.	 Analyses	were	performed	at	day	8	of	culture.	After	equilibrating	the	cells	for	1h	at	37°C	in	the	Seahorse	test	 medium,	 the	 mitochondrial	 stress	 protocol	 included	 sequential	 injection	 of	oligomycin	(2	μM	final)	to	inhibit	ATP	synthase,	FCCP	(1	μM	final)	as	the	uncoupling	agent	and	a	final	injection	of	Amytal	(1	mM	final)	and	Antimycine	A	(0.5	μM	final).	For	the	 glycolytic	 reserve	 assessment	 protocol,	 Cells	 were	 deprived	 of	 glucose	 in	 a	 non-buffered	medium	for	one	hour	before	the	analysis.	Glucose	was	injected	first	at	10	mM	final	to	measure	glycolysis.	Glycolytic	capacity	was	measures	as	the	maximal	ECAR	value	after	 oligomycin	 injection	 (2	μM	 final),	 effectively	 shutting	 down	 ATP	 production	 by	oxidative	phosphorylation.	Glycolytic	reserve	is	defined	as	the	difference	between	basal	glycolysis	and	glycolytic	capacity.	The	final	injection	is	2-deoxy-glucose	(2-DG)	at	50	mM	to	 inhibit	 glycolysis.	All	ECAR	values	 are	 given	after	deduction	of	non-glycolytic	ECAR	measurement.		
Cloning	 of	 mouse	 Nmrk2	 promoter	 in	 luciferase	 reporter	 plasmid	 and	 transfection	
procedure	The	transcription	initiation	site	of	mouse	Nmrk2	promoter	was	determined	by	5’RACE	and	was	conform	to	the	reported	site	in	the	Genebank	(NM_027120.2).	The	promoter	of	the	mouse	Nmrk2	gene	was	cloned	from	C57Bl6/N	genomic	DNA	by	PCR	with	forward	primer	 CCTATGAGGTGAGAGGATCTCTG	 (-3009/-2987)	 and	 reverse	 primer	CTTGGGGACTGGAGGTGACTGGTC	 (+61/+38),	 and	 inserted	 into	 a	 pGL4.10[luc2]	luciferase	 reporter	 plasmid	 (Promega	 prod	 no	 E6651).	 Subsequent	 deletions	 were	performed	 by	 enzymatic	 digestion	 or	 primer	 mediated	 subcloning	 of	 the	 original	fragment.	 2.5	 x	 105	 cardiomyocytes	 in	 12-well	 plates	were	 co-transfected	 at	 day	 2	 of	culture	 with	 1	 μ g	 of	 Nmrk2	 pGL4.10[luc2]	 constructs	 and	 100	 ng	 of	pGL4.73[hRluc/SV40]	 Vector	 (Promega	 prod	 no	 E6911)	 as	 an	 internal	 control	 of	transfection	 efficiency	 using	 Lipofectamine	 2000	 (Lifetechnology)	 as	 indicated	 by	 the	
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supplier.	In	the	case	of	AICAR	treatment,	Luciferase	activity	was	analyzed	48h	later	with	the	Dual-Luciferase	Assay	System	(Promega).		
AMPK,	PPAR,	RXR	Vectors	The	pcDNA3	vectors	harboring	dominant	negative	AMPK,	PPARα,	PPARβ	and	PPARγ	as	well	as	RXR	genes	were	kindly	provided	by	Pr.	M.	Raymondjean	and	collaborator,	Dr	M.	 Foretz.4-6	 These	 vectors	were	 co-transfected	 at	 a	 dose	 of	 100	 ng	 /	well	 in	 24-well	plates	with	500ng	of	Nmrk2	luciferase	constructs.		
Cloning	of	mouse	Nmrk2	cDNA	into	recombinant	adenovirus	The	cDNA	of	Nmrk2	was	cloned	by	PCR	amplification	from	reversed	transcribed	cardiac	mRNA	 into	pcDNA3HA	vector,	 introducing	a	MYPYDVPDYALMAMEARIR	sequence	 (HA	tag	is	underlined)	at	the	N-terminus	of	Nmrk2	open	reading	frame	that	replaced	the	first	methionine.	The	HA	tagged	Nmrk2	cDNA	was	then	subcloned	into	the	pShuttle2	vector	before	 to	 be	 inserted	 in	 the	 Adeno-X	 viral	 DNA	 (Clontech	 lab.	 Adeno-X	 Expression	System	 1).	 Pac1	 Linearized	 recombinant	 adenoviral	 DNA	was	 transfected	 in	HEK	 293	cells	followed	by	rounds	of	infection	to	collect	the	adenoviral	particles.	Adenoviral	titer	was	determined	by	the	cytopathic	effect	method.	NRCs	were	infected	at	day	3	of	culture	with	100	particles/cell.		
Mitochondrial	(mtDNA)	and	nuclear	(nDNA)	DNA	content	Total	 DNA	was	 extracted	 from	 left	 ventricle.	 Briefly,	 tissue	were	minced	 in	 500μl	 of	buffer	1	(TrisHCl	10	mM,	NaCl	10	mM,	EDTA	25	mM,	SDS	1%,	proteinase	K	0.4mg/ml,	pH	7.5)	with	cleaned	scissors	and	incubated	overnight	at	37°C.	After	addition	of	50μl	of	saturated	NaCl	solution,	the	homogenates	were	centrifuged	at	500	g	for	15	minutes.	Isopropanol	(500μl)	was	added	to	supernatants	which	were	then	incubated	45	minutes	at	 -20°C.	 After	 a	 centrifugation	 at	 16000	 g	 for	 20	 minutes,	 the	 pellets	 were	 kept,	washed	with	ethanol	70%,	resuspended	in	buffer	2	and	finally	warmed	at	70°C.	mtDNA	content	 was	 measured	 by	 real-time	 qPCR	 using	 specific	 primers	 for	 a	 mitochondrial	gene	 (Dloop,	 forward	 primer	 ATAGCCGTCAAGGCATGAAA,	 reverse	 primer	GATTGGGTTTTGCGGACTAA)	and	a	nuclear	 gene	 (B2M	 (beta-2-microgobulin),	 forward	primer	TGGTAAAGCAAAGAGGCCTAA,	reverse	primer	AGAAGTAGCCACAGGGTTGG).	The	difference	between	the	threshold	cycle	(Ct)	of	nuclear	gene	and	mtDNA	gene	(ΔCt)	was	used	 to	 assess	 the	 mtDNA/nDNA	 ratio,	 which	 was	 calculated	 using	 the	 following	formula:	2(2ΔCt).	For	details	see.7			
Measure	of	O2	consumption	rate	in	permeabilized	cardiac	fibers	Mitochondrial	respiration	was	studied	in	situ	 in	saponin-permeabilized	cardiac	muscle	fibres	 using	 a	 Clarke	 electrode	 as	 previously	 described.8	 Oxygen	 consumption	 was	measured	 after	 successive	 addition	 of	 pyruvate-malate	 (1-4	 mM),	 ADP	 (0.1	 mM),	creatine	(12	mM),	ADP	(2	mM),	glutamate	(10	mM),	succinate	(15	mM),	and	amytal	(an	inhibitor	 of	 complex	 I,	 1	 mM)	 to	 respiration	 solution	 (in	 mM:	 2.77	 CaK2EGTA,	 7.23	K2EGTA	[100	nM	free	Ca2+],	6.56	MgCl2	[1	mM	free	Mg2+],	20	taurine,	0.5	DTT,	50	K-methane	 sulfonate	 [160	mM	 ionic	 strength],	 20	 imidazole,	 pH	 7.1)	 at	 23°C.	 From	 this	protocol,	 sensitivity	 of	 mitochondrial	 respiration	 to	 external	 ADP	 and	 creatine	 were	determined	(Km	ADP	and	Km	creatine)	and	acceptor	control	ratio	(ACR)	was	calculated	from	basal	mitochondrial	respiration	rate	(in	the	presence	of	pyruvate/malate	1/4	mM,	
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without	ADP)	and	oxygen	consumption	after	addition	of	2mM	ADP.	Rates	of	respiration	are	given	in	nmoles	O2/min/mg	dry	weight.		
Biochemical	studies	Frozen	 tissue	 samples	 were	 weighed,	 homogenized	 (Bertin	 Precellys	 24)	 in	 ice-cold	buffer	(50	mg/ml)	containing	HEPES	5	mM	(pH	8.7),	EGTA	1	mM,	DTT	1	mM	and	0.1%	Triton	X-	100.	Citrate	synthase	(CS),	complex	I	and	cytochrome	oxidase	(COX),	activities	were	 determined	 in	 homogenized	 ventricles	 as	 previously	 described.8	 Activities	 of	enzymes	were	 determined	 by	 standard	 spectrophotometric	 assays.	 Briefly,	 for	 citrate	synthase	(CS),	approximately	0.5μg	of	protein	were	added	in	1	ml	of	Buffer	M	(Trizma	100	 mM	 (pH8),	 5,5’-dittiobis-(2-Nitrobenzenoic	 acid)	 0.1	 mM,	 Acetyl-CoA	 0.3	 mM,	oxaloacetic	 acid	 0.5mM)	 and	 the	 absorbance	 at	 412	 nm	was	measured	 during	 3	min.	Cytochrome	 oxidase	 (COX)	 activity	 was	 determined	 by	 the	 addition	 of	 approximately	0.25	μg	of	protein	in	1	ml	of	phosphate	buffer	(K2HPO4	50	mM	(pH	7.4))	containing	50	
μM	 Cytochrome	 c	 (cytochrome	 c	 were	 previously	 reduced	 at	 90%	 using	 sodium	dithionite).	Loss	of	reduced	cytochrome	c	were	followed	by	measuring	the	absorbance	at	 550	 nm	 during	 3	min	 using	 fully	 oxidized	 cytochrome	 c	 (by	 addition	 of	 potassium	ferricyanure	in	excess)	as	a	reference.	For	the	determination	of	complex	I	activity,	25	μg	of	protein	 and	100	μM	NADH	were	added	 to	1	ml	of	C1	Buffer	 (41.1	mM	KH2PO4,	K2HPO4	8.8	mM,	Decyl-ubiquinone	100μM,	BSA	3.75	mg/ml,	pH	7.4).	Measurements	of	the	 absorbance	 at	 340	 nm	during	 3	min	 in	 the	 presence	 and	 in	 the	 absence	 of	 5	mM	rotenone	were	used	to	calculate	activity	of	this	complex.	CS,	COX	and	complex	I	activities	were	 respectively	 calculated	using	an	extinction	coefficient	of	13600	M-1.cm-1,	18500	M-1.cm-1	and	6220	M-1.cm-1	and	rates	are	given	in	international	unit	(IU)/g	prot.	ATP	citrate	lyase	activity	was	quantified	in	1	ml	of	assay	buffer	(100	mM	Tris-HCl,	pH	8.7,	20	mM	Potassium	 citrate	monobasic,	 10	mMdithiothreitol,	 10	mM	MgCl2,	 500	unit/ml	 of	Malic	Dehydrogenase	 from	porcine	 heart	#M1567	 from	SIGMA,	 330	μM	Coenzyme	A	sodium	salt	hydrate,	5	mM	ATP,	140	μM	NADH)	by	measurement	of	the	absorbance	at	340	nm	during	3	min	before	and	after	the	addition	of	200	μM	SB	204990	inhibitor	of	ACL	(TOCRIS,	Cat.	No.	4962).	The	difference	between	the	slopes	of	the	2	measurements	was	used	to	calculate	activity	of	ACL	using	an	extinction	coefficient	for	NADH	of	6220	M-1.cm-1.			
Liquid	 chromatography	 coupled	 to	 mass	 spectrometry	 (LCMS)	 analyses	 of	 NAD	
metabolome.		NAD-related	metabolites	were	quantified	as	previously	described	with	a	Waters	Acquity	LC	 interfaced	 with	 a	 Waters	 TQD	 MS	 operated	 in	 positive	 ion	 multiple	 reaction	monitoring	mode.9	Metabolites	were	 extracted	 as	 follows:	 pieces	 of	myocardial	 tissue	(≈10	 mg)	 were	 snap	 frozen	 and	 pulverized	 in	 liquid	 nitrogen.	 Metabolites	 were	extracted	 in	 10	 volumes	 (μ l	 /	 mg	 of	 tissue	 powder)	 of	 buffered	 ethanol	 (75%	ethanol/25%	10	mM	HEPES,	pH	7.1,	v/v)	preheated	to	80	°C.	Samples	were	shaken	at	1000	rpm	in	an	80	°C	block	for	three	minutes.	Soluble	metabolites	were	separated	from	particulate	by	refrigerated	microcentrifugation	(10	min,	16kg).	Extracts	were	dried	via	speed	 vacuum	 for	 three	 hours	 before	 to	 be	 processed	 for	 the	 LCMS	 analysis.	 This	method	 does	 not	 effectively	 preserve	 reduced	 co-factors.	 Hence	 NADH	 and	 NADPH	levels	were	not	reported	in	this	assay.		
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Vascular	reactivity	measurement	Mice	 were	 anesthetized	 by	 intraperitoneal	 injection	 of	 pentobarbital	 (150	 mg/kg).	Mesenteric	 bed	 was	 quickly	 isolated	 and	 placed	 in	 an	 ice-cold	 “Krebs”	 solution	 of	following	composition	(in	mmol/L):	NaCl	119,	KCl	4.7,	CaCl2(H2O)2	2.5,	MgSO4(H2O)7	1.2,	KH2PO4	1.2,	glucose	11,	NaHCO3	25,	bubbled	with	95%	O2	and	5%	CO2	to	maintain	pH	at	7.4.	First	order	mesenteric	arteries	(inner	diameter	100	–	300	μm)	were	carefully	dissected,	cleaned-off	from	fat	tissue	and	cut	into	1-2	mm	segments.	Each	segment	was	mounted	 in	 the	 chamber	of	 a	 small	 vessel	myograph	 (620	M,	Danish	Myo	Technology	A/S,	 Aarhus,	 Denmark)	 using	 25	 μm	 tungsten	 wire,	 as	 described	 previously.10	Chambers	were	filled	with	Krebs	solution,	bubbled	with	95%	O2	-	5%	CO2	mixture	and	kept	at	37°C.	Data	were	digitized	using	a	Powerlab	8/30	(AD	Instruments,	Paris,	France)	and	 acquired	 using	 the	 Labchart7	 software	 (AD	 Instruments).	 Vessels	 underwent	 a	normalization	procedure	which	consisted	in	stretching	the	vessels	stepwise	to	construct	tension	 –	 circumference	 relationship.	 Rings	 were	 eventually	 set	 at	 an	 internal	circumference	 corresponding	 to	 90%	 of	 the	 circumference	 the	 vessel	 would	 have	 if	submitted	 to	 a	 transmural	 pressure	 of	 100	 mmHg	 (13.3	 kPa).	 After	 an	 equilibration	period	of	45-60	min,	contractile	responses	of	the	vessels	were	evaluated	by	challenging	them	either	with	increasing	extracellular	[K+]	(using	modified	Krebs	solution	containing	various	amount	of	KCl,	with	equimolar	substitution	of	NaCl).	Other	vessels	were	treated	with	 increasing	 concentrations	 of	 the	 thromboxane	 A2	 mimetic	 U46619	 (Interchim,	Montluçon,	 France),	 added	 cumulatively.	 All	 vessels	 were	 then	 washed	 with	 Krebs	solution	 and	 contracted	 again	 with	 U46619	 (3.10-7	 mol/L).	 Relaxant	 responses	 to	cumulative	concentrations	of	either	carbachol	(Cch,	muscarinic	receptor	agonist,	Sigma-Aldrich)	 or	 (2-(N,N-Diethylamino)-diazenolate-2-oxide	 diethylammonium	 salt	 (DEA-NO),	a	nitric	oxide	donor	(Enzo	Life	Sciences,	Villeurbanne,	France)	were	then	evaluated.	Contractile	 responses	were	expressed	 in	mN/mm	or	relative	 to	response	 to	a	solution	containing	 120	 mmol/L	 extracellular	 [K+].	 Relaxant	 responses	 were	 expressed	 in	 %,	relative	 to	 the	 starting	 contraction	 amplitude	 obtained	 with	 3.10-7	 mol/L	 U46619.	Concentration-response	curves	were	fitted	with	the	Hill	equation	using	Prism7	software	(GraphPad	 software,	 Inc.,	 La	 Jolla,	 CA,	 USA),	 allowing	 to	 determine	 EC50	 (mol/L)	 and	maximal	 effect	 (Emax)	 for	 each	 experiment.	 Because	 for	 some	 responses	 the	 curve	fitting	was	not	successful,	corresponding	experiments	were	excluded	from	the	EC50	and	Emax	 analysis.	 All	 data	were	 expressed	 as	mean	 ±	 SEM	 of	 N	 experiments,	 where	 “N”	represents	 the	 number	 of	 animals.	 Statistical	 analysis	 was	 performed	 using	 Prism7.	Mann-Whitney	test	was	used	to	compare	EC50	and	Emax.	Also	concentration-response	curves	were	compared	using	2-way	ANOVA.		
Statistical	Analyses	For	 in	 vivo	 experiments,	 animals	 were	 randomly	 assigned	 into	 different	 treatment	groups.	To	assess	significance,	we	performed	Student’s	 t	 test	 for	 independent	samples	when	the	experimental	design	compared	only	2	groups,	or	One-Way	ANOVA	for	multiple	group	comparisons,	or	Two	Way	ANOVA	for	independent	factors	when	appropriate	for	the	experimental	design.	Tukey	tests	were	used	for	comparison	of	specific	experimental	groups	when	One-way	ANOVA	gave	a	p	value	<	0.05	or,	in	the	case	of	Two	Way	ANOVA	for	interaction	p	value	<	0.05.	Values	are	expressed	as	mean	±SEM.	
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Table	I.	Patients’	characteristics.		
Patients 
	
Pathology 
	
Age 
	
Sex 
	
NYHA	
class 
CHF	
duration 
LVEF 
	
BNP	 
pg/ml 
Treatments 
	1 Cad 49 M 4 90	Mo 15	% 320 Ramipril 2 Cad 63 M 3 4	Mo 30	% 157.8 Enalapril 3 Nocm	 56 M 3 28	Mo 35	% 500 Ramipril,	Carvedilol 4 Hdcm 48 F	 4 29	Mo 23	% 1249 Perindopril,	Carvedilol 
	Cad:	coronary	artery	disease,	Nocm:	non-obstructive	cardiomyopathy,	Hdcm:	hypertrophic	dilated	cardiomyopathy.	LVEF:	left	ventricular	ejection	fraction.	Human	cardiac	tissue	control	samples	(LV,	mean	age	51	years	±	4.5,	S.D,	not	in	the	table)	were	obtained	from	general	organ	donors	whose	non-diseased	hearts	were	explanted	to	obtain	pulmonary	and	aortic	valves.		
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Table	II.	Expression	level	of	genes	involved	in	NAD	homeostasis 
 Probe	Set	ID Gene	
Symbol 
Gene	Title Mut	
D8 
Mut	
D25 
Mut	
D25	
+PE 
	 Cont 
D25	
+PE 
1452944_at 	Afmid	///	Syngr2 arylformamidase	///	synaptogyrin	2 1.19 0.78 0.92 	 0.65 
1447638_at 	Afmid	///	Syngr2 arylformamidase	///	synaptogyrin	2 0.99 0.90 0.88 	 0.92 
1428885_at 	Afmid	///	Syngr2 arylformamidase	///	synaptogyrin	2 1.31 0.97 1.08	 	 0.97 
1431722_a_at Afmid arylformamidase 0.97 1.01 0.96	 	 0.99 
1432492_a_at Haao 3-hydroxyanthranilate	3,4-dioxygenase 0.99 0.99 0.98 	 1.00 
1420437_at Ido1 indoleamine-pyrrole	2,3	dioxygenase	1 0.83 1.09 0.99 	 1.01 
1425778_at Ido2 indoleamine-pyrrole	2,3	dioxygenase	2 0.99 0.96 0.95 	 0.97 
1418998_at Kmo kynurenine	3-monooxygenase	(kynurenine	3-hydroxylase) 0.99 0.98 0.97 	 1.00 
1430570_at Kynu kynureninase	(L-kynurenine	hydrolase) 1.00 0.94 0.93 	 0.96 
1451903_at Kynu kynureninase	(L-kynurenine	hydrolase) 1.00 0.99 0.97 	 1.00 
1430359_a_at Nadsyn1 NAD	synthetase	1 1.00 0.89 0.85 	 0.92 
1417190_at Nampt nicotinamide	phosphoribosyl	transferase 1.02 1.10 0.87 ¶ 1.35 
1448607_at Nampt nicotinamide	phosphoribosyl	transferase 1.33 1.41 0.99 	 1.14 
1454748_at Naprt1 nicotinate	phosphoribosyltransferase	domain	containing	1 0.64 0.86 0.86 	 1.06 
1425773_s_at Nmnat1 nicotinamide	nucleotide	adenylyltransferase	1 0.85 0.92 0.89 	 1.00 
1429819_at Nmnat1 nicotinamide	nucleotide	adenylyltransferase	1 0.96 1.05	 1.05 	 1.05 
1436155_at Nmnat2 nicotinamide	nucleotide	adenylyltransferase	2 0.78 1.00 0.95 	 0.98 
1424899_at Nmnat3 nicotinamide	nucleotide	adenylyltransferase	3 1.11 0.79 0.67 	 0.73 
1432342_at Nmnat3 nicotinamide	nucleotide	adenylyltransferase	3 1.00 0.97 0.97 	 0.98 
1443149_at Nmnat3 Nicotinamide	nucleotide	adenylyltransferase	3	(Nmnat3).	mRNA 0.99 0.98 0.97 	 1.00 
1459128_at Nmnat3 Nicotinamide	nucleotide	adenylyltransferase	3	(Nmnat3).	mRNA 0.99 0.92 0.90 	 0.96 
1432342_at Nmnat3 nicotinamide	nucleotide	adenylyltransferase	3 1.00 0.97 0.97	 	 0.98 
1443149_at Nmnat3 Nicotinamide	nucleotide	adenylyltransferase	3	(Nmnat3).	mRNA 0.99 0.98 0.97 	 1.00 
1459128_at Nmnat3 Nicotinamide	nucleotide	adenylyltransferase	3	(Nmnat3).	mRNA 0.99 0.92 0.90 	 0.96 
1425646_at Nmrk1	 nicotinamide	riboside	kinase	1 0.98 0.90 0.91 	 1.01 
1447503_at Nmrk1 nicotinamide	riboside	kinase	1 1.00 0.99 0.92 	 0.98 
1453898_at Nmrk2 nicotinamide	riboside	kinase	2 8.87 30.6 57.4 ¶ 4.15 
1422974_at Nt5e	 5'	nucleotidase.	ecto	(CD73) 1.48 2.80 4.22 ¶ 1.21 
1428547_at Nt5e	 5'	nucleotidase.	ecto	(CD73) 1.06 1.63 2.42 	 0.94 
1416530_a_at Pnp	 purine-nucleoside	phosphorylase 0.76 0.83 0.74 	 0.92 
1453299_a_at Pnp	 Similar	to	purine-nucleoside	phosphorylase	/	LOC545044	 0.96 0.84 0.68 	 0.88 
1418836_at Qprt quinolinate	phosphoribosyltransferase 1.00 0.99 0.99 	 1.00 
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1418837_at Qprt quinolinate	phosphoribosyltransferase 1.00 0.99 0.98 	 1.00 
1419093_at Tdo2 tryptophan	2,3-dioxygenase 0.99 0.99 0.98 	 1.00 
1449337_at Tdo2 tryptophan	2,3-dioxygenase 0.99 0.99 0.98 	 1.00 
1455770_at Tdo2 Tryptophan	2,3-dioxygenase.	mRNA	(cDNA	clone	MGC:25811	IMAGE:4159877) 0.99 0.99 0.98 	 1.00 
 Control	 (Cont)	and	SRFHKO	mutant	 (Mut)	mice	were	sacrificed	at	day	 (D)	8	or	25	after	first	 day	 of	 tamoxifen	 injection.	 A	 group	 of	 control	 and	 a	 group	 of	mutant	mice	were	treated	with	phenylephrine	(PE)	from	D10	to	25	before	sacrifice.	RNA	was	extracted	and	processed	 for	 Affymetrix	 Mouse	 430.2	 Expression	 array.	 Genes	 with	 a	 fold	 change	expression	<	 or	 >	 to	 1.3	 and	 a	 p	 value	<	 0.05	 compared	 to	 non-treated	 time-matched	control	are	highlighted	in	bold	font,	green	for	upregulated	genes,	red	for	down-regulated	genes.	¶,	genes	differentially	regulated	between	Mutant	D25+PE	and	Control	D25+PE.	
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Table	 III.	 Pharmacological	 parameters	 CE50	 and	 Emax	 obtained	 by	 analysis	 of	
concentration-response	 curves	 of	 [K+],	 thromboxane	 mimetic	 U46619	 and	 NO	
donor	 DEA-NO	 in	 mesenteric	 artery	 rings	 isolated	 from	 NR-supplemented	 or	
control	mice. 	
	 [K+] U46619 carbachol DEA-NO 
Control 
N 6 6 4a 5 
CE50 24.7	±	2.7	mmol/L 18	±	8	nmol/L 1.7	±	0.6	 µmol/L 0.20	±	0.14	µmol/L 
Emax	
3.0	±	0.3	mN/mm 116	±	4	% 62	±	8	% 77	±	6	% 
NR 
N 5a 6 3a 5 
CE50	
31.2	±	4.0	mmol/L 19	±	8	nmol/L 0.5	±	0.1	 µmol/L 0.19	±	0.10	µmol/L 
Emax 3.0	±	0.3	mN/mm 121	±	15	% 53	±	6	% 81	±	3	% 
	Emax	 for	 U46619	 was	 expressed	 relative	 to	 the	 contraction	 amplitude	 obtained	 with	solution	containing	120	mmol/L	[K+].	Emax	for	carbachol	and	DEA-NO	were	expressed	in	%,	 relative	 to	 the	 starting	 contraction	 amplitude	 obtained	 with	 U46619	 (100%	corresponding	to	full	relaxation).	a:	because	for	some	responses	the	curve	fitting	was	not	successful,	corresponding	experiments	were	excluded	from	the	EC50	and	Emax	analysis.		
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Table	IV.	LCMS	analysis	of	hepatic	NAD	metabolome	from	control	and	SRFHKO	
mutant	mice	fed	with	regular	CD	diet	or	NR-enriched	diet.		
Liver	
(pmol/mg)	 Control	(n	=	4)	 Control	+	NR	(n	=	5)	 Mutant	(n	=	6)	 Mutant	+	NR	(n	=	5)	 Anova	NAD	 1615	±	432	 1916	±	636	 1163	±	40	 4245	±	1225	 §	NADP	 118	±	27	 105	±	23	 117	±	6	 159	±	15	 	NAAD	 5.2	±	1.7	 7.5	±	3.2	 1.7	±	0.4	 52.5	±	31.5	 	NMN	 6.7	±	3.2	 9.1	±	3.6	 2.5	±	0.4	 23	±	8.1	 §	ADPR	 107	±	21	 129	±	38	 89	±	13	 347	±	76	**	 §§,	i		Uridine	 43	±	7	 53	±	11	 58	±	5	 26	±	4	*	 	i	Cytidine	 2.5	±	0.7	 2.6	±	1	 3	±	0.4	 1	±	0.6	 	Inosine	 311	±	81	 344	±	54	 432	±	54	 489	±	56	 ¶	IMP	 196	±	35	 210	±	37	 311	±	32	 317	±	43	 ¶¶	UMP	 292	±	44	 222	±	25	 243	±	21	 223	±	15	 	CMP	 20.2	±	1.6	 18.2	±	3	 21.3	±	0.8	 16.5	±	1.4	 			NR		a				 2.7	±	0.9	 2.1	±	0.4	 1	±	0.5	 3.3	±	1.3	 	Nam	 479	±	126	 433	±	86	 355	±	124	 956	±	215	*	 i	MeNam	 4.2	±	0.6	 23.1	±	5.3	 3	±	0.7	 26.8	±	6.8	 §§	Me-4PY	b	 2.4	±	0.5	 11.7	±	2.8	 1.3	±	0.5	 17.6	±	3.2	 §§	
(a)	n=3	for	Mutant	(b)	n=4	for	Mutant		Liver	metabolite	extraction	was	performed	in	the	same	mice	than	those	analyzed	for	the	cardiac	metabolome	in	the	Figure	3	of	the	main	manuscript.	Statistics:	 2-way	 ANOVA	 for	 independent	 samples	 followed	 by	 post-hoc	 Tukey	 test:	Genotype	effect	is	indicated	by	¶	p≤0.05,	¶¶	p≤0.01;	NR	effect	is	indicated	by	§	p≤0.05,	§§	p≤0.01.	 Interaction	effect	 is	 indicated	by	 i	 p≤0.05.	Where	 interaction	was	detected,	post-hoc	Tukey	test	was	performed	between	 individual	groups:	*	p≤0.05	NR	vs	CD	 for	the	same	genotype.		
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Table	V.	Echocardiography	after	TAC	or	SHAM	surgery		 Baseline 2W 	 SHAM SHAM	+	NR TAC TAC	+	NR Anova SHAM SHAM	+	NR TAC TAC	+	NR Anova N 7 7 10 11 	 7 7 5 7 	IVSThD 0.6	±	0.02 0.6	±	0 0.6	±	0.02 0.6	±	0.02 ns 0.6	±	0.02 0.6	±	0.02	 0.9	±	0.04 0.9	±	0.04 ns LVEDD 3.2	±	0.08 3.2	±	0.1 3.3	±	0.08 3.4	±	0.07 ns 3.6	±	0.06 3.6	±	0.09 4.2	±	0.22 4.2	±	0.17 ¶¶ PWThD 0.6	±	0.02 0.6	±	0.02 0.6	±	0.04 0.6	±	0.04 ns 0.6	±	0.02 0.6	±	0.04 0.7	±	0.08 0.7	±	0.03 ¶¶ IVSThS 1	±	0.03 1.1	±	0.02 1	±	0.03 1.1	±	0.02 ns 1.1	±	0.03 1.1	±	0.03 1.2	±	0.06 1.2	±	0.06 ¶¶ LVESD 1.7	±	0.04 1.8	±	0.06 1.8	±	0.04 1.9	±	0.04 ns 2	±	0.04 2	±	0.05 3.2	±	0.26 3.1	±	0.22 ¶¶ PWThS 1.1	±	0.05 1.1	±	0.04 1.1	±	0.04 1	±	0.02 ns 1.1	±	0.04	 1	±	0.02 0.9	±	0.07 0.9	±	0.03 ¶¶ EDV 85	±	5.7 87	±	7.8 93	±	6 98	±	6 ns 115	±	5.7 123	±	9.2 192	±	30.9 184	±	20.5 ¶¶ ESV 13	±	1.8 14	±	2 18	±	2 17	±	1.4 ns 20	±	0 21	±	1.4 90	±	20 80	±	15	 ¶¶ LVEF	% 83	±	0.4 82	±	0.7 82	±	0.3 82	±	0.4 ns 82	±	0.4 83	±	0.3 55	±	3.8 59±	3.7 ¶¶ FS	% 46±	0.5 45	±	0.7 45	±	0.3 47	±	2.6 ns 45	±	0.4 45	±	0.32 24	±	2.3 27±	2.3 ¶¶ SV 71	±	5.1 71	±	7 75	±	4.3 84	±	4.9 ns 94	±	4.8 103	±	7.1 102	±	10.2 106	±	7.2 ns h/r 0.4	±	0.01 0.4	±	0.01 0.4	±	0.01 0.4	±	0.01 ns 0.3	±	0.01 0.3	±	0.02 0.4	±	0.03 0.4	±	0.02 ¶¶ HR 638	±	9.7 605	±	6.7 616	±	8.4 614	±	7.1 ns 638	±	9.7 629	±	12.8 549	±	37.8 591	±	12.3 ¶¶ CO 46	±	3.7 43	±	4.4 46	±	2.8 51	±	2.9 ns 60	±	3.3 65	±	4.4 55	±	2.3 62	±	3.6 ns LV	mass 54	±	1.8 55	±	3.4 59	±	5.2 58	±	4.3	 ns 66	±	3.2 67	±	5 136	±	13.7 126	±	9.8 ¶¶ 	 4w 6w N 7 7 5	 7 Anova 7 7 4 7 Anova IVSThD 0.6	±	0.02 0.7	±	0.02 0.9	±	0.04 0.8	±	0.02	**,	# ¶¶,	ii 0.6	±	0.02 0.6	±	0.02 0.8	±	0 0.9	±	0.02 ¶¶,	§§ LVEDD 3.5	±	0.09 3.7	±	0.1 4.3	±	0.33 4.4	±	0.2 ¶¶ 3.6	±	0.07 3.7	±	0.08 4.8	±	0.19 4.7	±	0.25 ¶¶ PWThD 0.5	±	0.02 0.6	±	0.03 0.8	±	0.08 0.8	±	0.07 ¶¶ 0.6	±	0.04 0.6	±	0.03 0.7	±	0.06 0.8	±	0.05 ¶¶ IVSThS 1.1	±	0.04 1.1	±	0.03 1.2	±	0.07 1	±	0.02 i 1.1	±	0.04 1.1	±	0.02 1.1	±	0.03 1.1	±	0.05 ns LVESD 1.9	±	0.05 2.1	±	0.06 3.5	±	0.47 3.5	±	0.23 ¶¶ 1.9	±	0.04 2.1	±	0.06 4.1	±	0.26 3.7	±	0.28 ¶¶ PWThS 1	±	0.04 1.1	±	0.04 1.1	±	0.07 1	±	0.03 ns 1.1	±	0.04 1	±	0.04	 0.8	±	0.05 1	±	0.05 ¶¶ EDV 109±	7.4 129	±	9.9 206	±	42.5 217	±	24.8 ¶¶ 119	±	5.9 139	±	6.7 272	±	28.7 270	±	35.4 ¶¶ ESV 19	±	1.4 23	±	1.8 128	±	39.2 116	±	19.1 ¶¶ 19	±	1.4 24	±	2 167	±	27.5 143	±	25.9 ¶¶	LVEF	% 82	±	0.5 81	±	0.3 46	±	9.1 48	±	3.7 ¶¶ 83	±	0.4 82	±	0.5 39	±	5.1** 50	±	3.7	**,	# ¶¶,	i FS	% 45	±	0.6 44	±	0.3 20	±	5.2 21	±	2 ¶¶ 45	±	0.5 45	±	0.5 16	±	2.6*** 22	±	2.1	**,	## ¶¶,	i SV 91	±	6.3 104	±	8.4 80	±	4.5 100	±	9 ns 97	±	5.2 110	±	4.4 105	±	6.5 130	±	11.3 ¶¶ h/r 0.3	±	0.01 0.4	±	0.02 0.4	±	0.04 0.4	±	0.01 ns 0.3	±	0.01 0.3	±	0.01 0.3	±	0.03 0.4	±	0.02 ¶¶ HR 645	±	11 636	±	10.8 575	±	20.7 586	±	20.9 ¶¶ 628	±	6.5 636	±	10.7 598	±	38.7 568	±	24.6 ¶¶ CO 59	±	4.7 67	±	6 46	±	1.6 62	±	2.9 § 61	±	3.3 70	±	3.3 63	±	6.2 74	±	7.6 ns LV	mass 62	±	3.6 80	±	3.8 156	±	22.6 141	±	15.8 ¶¶ 65	±	5.1 72	±	4.2 146	±	6.3 173	±	18.3 ¶¶ 	Abbreviations:	 IVSThD	 and	 IVSThD,	 interventricular	 septum	 thickness	 in	 diastole	 and	systole;	LVEDD	and	LVESD,	left	ventricle	end-diastolic	and	end-systolic	diameter;	PWTh,	LV	posterior	wall	thickness;	EDV	and	ESV,	end-diastolic	and	end-systolic	volume;	LVEF,	LV	 ejection	 fraction;	 FS,	 LV	 fractional	 shortening;	 h/r,	 LV	wall	 thickness/radius	 ratio;	HR,	heart	rate;	CO,	cardiac	output.	Two-way	factorial	ANOVA	for	independent	samples:	¶¶	p≤	0.01	for	the	TAC	effect;	§	p≤	0.05,	§§	p≤	0.01	for	the	NR	effect;	i	p<	0.05,	ii	p≤	0.01	for	 the	 interaction	 effect.	 ANOVA	 was	 followed	 by	 a	 post-hoc	 Tukey	 test	 when	interaction	was	significant:	**,	p≤	0.01,	***,	p≤	0.001	vs	the	SHAM	group;	#,	p≤	0.05,	##,	p≤	0.01	for	the	effect	of	NR	within	the	TAC	group.	 	
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Table	VI:	Antibody	list	
Target	protein Antibody	Supplier.	ref	# Dilution 
Acetyl-CoA	Carboxylase	(ACC) Thermoscientific.	#	MA5-15025	 1/1000 
ACC	Phospho-Ser79 Thermoscientific.	#	PA5-17725 1/1000 AMPKα Cell	Signaling	#2532 1/1000 
AMPKα	(Phospho-Thr172) Cell	Signaling	#2535 1/1000 
FKHR	(H-128)(FoxO1) Santa	Cruz	BT.	#	sc-11350 1/1000 
Ac-FKHR	(D-19): Santa	Cruz	BT..#	sc-49437 1/200 
Acetyl-Lysine Cell	Signaling	#9441 1/1000 
Citrate	Synthase Abcam 	
GAPDH Sigma	#G9545 1/3000 
Aconitase	2 Kind	gift	of	Anne	Laure	Bulteau (Bulteau	et	al.	Biochemistry.	
2003;42(50):14846-55) 
1/500	
HA	epitope Sigma	#H6908 1/500 NMRK2	 Generated	by	BioGenes	(see	below) 1/500 PARP	 Cell	Signaling	#9532 1/1000 PAR	(Anti-Poly	(ADP-Ribose) Pharmingen	#551813	 1/500 p53	(acetyl	K386)	 Abcam	#ab52172 1/500 
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Figure	 I.	 NR	 supplementation	 did	 not	 alter	 vascular	 reactivity	 of	 isolated	
mesenteric	artery	rings.	Vasomotor	response	curves	to	increasing	concentrations	of	K+	(A),	 the	 thromboxane	mimetic	U46619	 (B),	 the	muscarinic	 receptor	 agonist	 carbachol	(Cch,	C)	or	the	NO	donor	diethylamine-nonoate	(DEA-NO,	D)	were	studied	on	mesenteric	artery	 rings	 isolated	 from	NR-supplemented	mice	 (NR,	 filled	 squares)	 or	 control	mice	(Control,	 empty	 circles).	 In	 B,	 contraction	 was	 expressed	 relative	 to	 the	 contraction	amplitude	 obtained	 with	 solution	 containing	 120	 mmol/L	 [K+].	 In	 C	 and	 D,	 relaxant	responses	 were	 expressed	 in	 %,	 relative	 to	 the	 contraction	 amplitude	 obtained	 with	U46619.	 Data	 are	mean	 ±	 SEM	 of	N=5-6	 animals.	 No	 significant	 difference	was	 found	between	NR	and	control	groups	in	any	of	the	response	tested	(2-way	ANOVA).	
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Figure	 II.	 Histological	 assessment	 of	 cardiomyocytes	 shape	 in	 SRFHKKO	 mice	 fed	
with	control	diet	or	NR-enriched	diet	compared	to	control	mice	on	regular	control	
diet.	 (A)	Transverse	heart	 section	 taken	 in	 the	middle	 region	between	apex	and	base	were	 stained	 with	 Anti	 h1-Vinculin	 staining	 was	 used	 to	 label	 cardiomyocytes	sarcolemma	and	intercalated	disks.	Confocal	images	were	acquired	in	the	middle	of	the	posterior	 wall	 of	 the	 LV	 were	 cardiomyocytes	 are	 cut	 in	 the	 longitudinal	 axis.	 (B)	Cardiomyocytes	area,	(C)	length	(Feret)	and	(D)	width	(minFeret)	were	calculated	using	Image	 J	 software	 in	 3	 independent	 mice	 for	 each	 group.	 Statistics:	 A	 Chi2	 test	 was	applied	to	test	the	frequency	distribution	of	cardiomyocytes.	Alpha	level	was	adjusted	to	1.67E-2	 (0.05	 /	 3	 comparisons).	 Control	 N=3,	 148	 cardiomyocytes;	 Mut	 SFRHKO	 N=3	individual,	113	cardiomyocytes;	Mut	SRFHKO	+	NR,	N=3	individuals,	132	cardiomyocytes.			
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Figure	 III.	 Cardiac	NAD+	 and	NADH	quantification	 in	 control	 and	 SRFHKO	mice	 at	
day	50	following	45	days	of	NR	enriched	diet.		Cardiac	 metabolites	 were	 extracted	 by	 the	 boiling	 method	 in	 buffered	 ethanol.	 The	extracts	containing	the	sum	of	free	NAD+	and	NADH	(total	free	NAD)	or	NAD+	only	after	selective	 heat	 degradation	 of	 NADH	 in	 acid	 conditions	 were	 quantified	 by	 the	colorimetric	alcohol	dehydrogenase	NAD	recycling	assay.	NADH	levels	were	calculated	by	the	substraction	of	quantified	NAD+	levels	from	total	NAD.	(A)	NAD+	values	in	pmole/	mg	of	heart	tissue;	control	CD	n=6,	control	NR	n=6,	SRFHKO	CD	n=6,	SRFHKO	NR	n=5.	
(B)	NADH	values	in	pmole/	mg	of	heart	tissue,	control	CD	n=5,	control	NR	n=6,	SRFHKO	CD	 n=5,	 SRFHKO	 NR	 n=4.	 (C)	 NAD+/NADH	 ratio.	 Two-way	 factorial	 ANOVA	 for	independent	samples:	¶¶	p≤	0.01	for	the	genotype	effect;	§§	p≤	0.01	for	the	NR	effect.			 	
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Figure	IV.	Acetylation	and	parylation	level	of	cardiac	proteins	Equal	quantities	of	cardiac	proteins	from	control	and	SRFHKO	mice	fed	with	regular	diet	(CD	or	NR	enriched	diet	were	extracted	at	D45	and	analyzed	by	SDS-PAGE.	
(A)	Western	blot	analysis	using	an	anti-PAR	antibody		
(B)	 Western	 blot	 analysis	 using	 an	 anti-acetyl-Lysine	 antibody.	 Arrows	 on	 the	 right	points	to	bands	whose	signal	is	increased	in	NR-fed	animals	compared	to	CD	diet.	
(C)	Western	blot	for	GAPDH	is	shown	as	a	loading	control.	
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Figure	 V.	Western	 blot	 analysis	 for	 Acetyl-p53	 protein	 in	 cardiac	 extracts	 from	
control	and	and	SRFHKO	mice	fed	with	control	CD	diet	or	NR-diet.	Top:	anti-acetyl	p53	immunoblot.	Bottom:	Ponceau	staining	is	shown	for	loading	control	
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Figure	 VI.	 Western	 blot	 analysis	 for	 mitochondrial	 proteins	 in	 cardiac	 extracts	
from	control	and	SRFHKO	mice	fed	with	control	CD	diet	or	NR-diet.	(A)	Mouse	anti-Acetyl-Lysine	 (K103)	 immunoblot	 of	 supernatant	 and	 eluate	 of	 immunoprecipitated	cardiac	protein	extract	with	preiimmune	rabbit	IgG.		(B)	Citrate	synthase	immunoblot.	N=3	for	each	group.	Right	graphs	show	quantification	performed	with	Image	J	software	following	the	background	substraction	method.	Two-way	factorial	ANOVA	for	independent	samples.	¶	p≤	0.05	for	the	genotype	effect.		 	
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Figure	 VII.	 Impact	 of	 NR	 on	 genes	 involved	 in	 energy	 metabolism	 and	
mitochondrial	respiration	in	permeabilized	fibers.	LV	tissue	were	harvested	in	control	and	SRFHKO	mice	fed	with	regular	chow	diet	(CD)	or	NR	 from	D5	 to	 day	 45	 and	 split	 for	RTqPCR	 analysis	 or	 isolation	 of	 cardiac	 fibers	 for	respiration	 studies	 (Figure	 3	 and	 S3).	 (A-C)	 RT	 qPCR	 analysis	 of	 transcriptional	regulators	of	energy	metabolism	(A).	Genes	 involved	 fatty	acid	beta-oxidation	 (B)	and	glycolysis	(C).	(D-G)	Cardiac	fibers	were	isolated	from	adults	LV	45	days	after	tamoxifen	injection	in	control	and	SRFHKO	mice	fed	with	regular	chow	diet	(CD)	or	NR	enriched	diet	(NR)	 in	the	same	series	of	mice	than	shown	in	Figure	3R-U.	 (D)	Rate	of	mitochondrial	oxygen	 consumption	 in	 permeabilized	 cardiac	 fibers	 using	 a	 Clarke	 electrodes	 after	successive	 addition	 of	 indicated	 substrates.	 Individual	 samples	 were	 analyzed	 in	triplicates	(n=5	individuals	for	each	group).	(E)	Km	ADP.	(F)	Km	Creatine.	(G)	Acceptor	control	ratio	for	ADP	(ACR).	 	Two-way	factorial	ANOVA	for	independent	samples.	¶	p≤	0.05,	¶¶¶	p≤	0.001	for	the	genotype	effect.		
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Figure	VIII.	NR	 impact	 in	adult	rat	cardiomyocytes.	NAD	(A)	and	Nmrk2	mRNA	(B)	levels	 in	adult	rat	cardiomyocytes	(ARC).	ARC	were	 treated	with	10	µM	FK866,	20	µM	azaserin	 or	 1	 mM	 NR	 for	 65	 h.	 NAD	 (NAD+	 +	 NADH)	 was	 extracted	 by	 the	 boiling	buffered	ethanol	method.	Data	are	given	as	µM	concentration	in	cells	using	an	average	30	pl	cellular	volume¶,	¶¶:	One-Way	ANOVA	statistic	p<	0.05,	and	p<0.01,	respectively.	**,	 ***,	 p<	 0.01	 and	 <	 0.001,	 respectively	 for	 post-hoc	 Tukey	 test	 between	 any	 group	versus	NT	control	cells;	ns	non-significant.		
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Figure	IX.	Impact	of	NR	on	NRC	oxygen	consumption	rates	following	mitochondrial	
stress	protocol.	This	figure	complements	Figure	4	of	the	main	manuscript.	NRC	grown	on	 Seahorse	 96	 well	 plates	 were	 analyzed	 at	 day	 8	 after	 5	 days	 of	 treatment.	 (A)	Coupling	efficiency	is	measured	as	(ATP	Production	Rate)	/	(Basal	Respiration	Rate).	(B)	Spare	 respiratory	 capacity	 is	 (Maximal	 Respiration)	 –	 (Basal	 Respiration).	 (C)	 Spare	respiratory	 capacity	 as	 a	%	 is	defined	as	 (Maximal	Respiration)	 /	 (Basal	Respiration).	
(D)	 Non	 mitochondrial	 oxygen	 consumption	 rate	 is	 the	 minimum	 rate	 measurement	after	 inhibition	 of	 respiration	 with	 rotenone	 and	 antimycin	 A.	 (E)	 Proton	 leak	 is	calculated	as	the	(minimum	rate	measurement	after	Oligomycin)	–	(non-mitochondrial	respiration).	N=	10	for	each	group.	¶,	¶¶,	¶¶¶:	One-Way	ANOVA	statistic	p<	0.05,	<0.01	and	<	0.001,	respectively.	**,	***,	p<	0.01	and	<	0.001,	respectively	 for	post-hoc	Tukey	test	 between	 any	 group	 versus	 NT	 control	 cells.	 #,	 ###,	 p	 <	 0.05,	 and	 <	 0.001,	respectively	for	post-hoc	Tukey	test	 for	other	comparisons,	notably	NR	100	µM	versus	FK866	10	µM	+	NR	100	µM	and	FK	10	µM	versus	FK866	10	µM	+	NR	250	µM.	
	
